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The conversion of epithelial cells into migratory and invasive 
mesenchymal cells has been established as a fundamental step in the metastatic 
cascade. In cancer cells the induction of an epithelial-to-mesenchymal transition 
(EMT) awards invasive properties that allow dissemination from the primary 
tumor, and promotes acquisition of stem-cell-like properties and prosurvival 
mechanisms that contribute to therapeutic resistance, relapse, and decreased 
overall survival. Identifying inhibitors that block EMT is of great therapeutic 
interest to prevent disseminated tumor cells and target dormant cancer stem 
cells. Efforts to rationally target EMT in the clinic have been impeded by our 
incomplete understanding of the molecular mechanisms regulating EMT in 
normal and cancerous cells.  
Here we develop a zebrafish in vivo EMT reporter for rapid screening of 
small molecules called Tg(snai1b:GFP), which labels snai1b-expressing cells 
during development undergoing EMT from the dorsal neural tube to form neural 
crest (NC). We identified a multi-kinase inhibitor, called TP-0903, that potently 
blocked EMT, migration, and differentiation of dorsal neural tube progenitors by 
activating retinoic acid (RA) signaling. We show for the first time that RA directly 
controls EMT of NC cells in vivo. Our findings designate RA as an attractive 
therapeutic strategy to antagonize EMT-dependent pathways and stem-cell-like 
 
iv 
properties to eliminate residual cancer stem cells and metastatic disease. 
 TP-0903 was rationally designed to target AXL RTK, a key oncogenic 
target that promotes EMT and metastasis. In NC derived cancers like melanoma, 
AXL can mediate invasion and promote resistance to targeted therapies in vitro. 
We hypothesize AXL promotes malignant melanoma by inducing EMT of cancer 
cells in vivo. To test this we generated a zebrafish melanoma model 
overexpressing AXL. We found AXL accelerated melanocyte transformation, 
tumor onset, growth and invasion. Additionally, we found that AXL did not 
activate EMT programs in vivo, despite numerous studies implicating AXL as a 
driver of EMT in vitro. Nevertheless these studies specify AXL as a driver of 
melanoma and establish an in vivo zebrafish model of AXL dependent melanoma 
invasion. This preclinical model will help determine the AXL dependent 
mechanisms driving malignant melanoma and evaluate effective AXL inhibitors to 
treat melanoma patients.   
 To my parents, my greatest source of inspiration.
 “Above all, don't fear difficult moments. 
The best comes from them.” 
Rita Levi-Montalcini 
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Metastasis 
Metastasis is the most difficult stage of cancer to treat and is the leading 
cause of death in solid tumor patients. Tumor cells become metastatic by 
acquiring genetic and epigenetic alterations that confer the ability to escape the 
primary tumor, survive passage in the bloodstream, extravagate through the 
capillary endothelium and colonize distant sites (Fidler, 2003). This multistep 
process depends on complex biological and biochemical changes in the cell as 
well as in the surrounding stroma that are still not completely understood. 
Understanding the molecular mechanisms that promote metastasis is necessary 
to develop targeted therapies against this disease. Advances in the molecular 
profiling of cancer using genomic approaches have identified genes necessary 
for the successful execution of the metastatic cascade (Weigelt et al., 2005). 
These findings implicate numerous pathways in metastatic progression and have 
increased the feasibility of identifying stages of metastasis that may be 
susceptible to therapeutic intervention.  
  
Epithelial-to-mesenchymal transition 
One stage of metastasis that has recently emerged at the forefront of 
cancer research is the epithelial-to-mesenchymal transition (EMT). EMT is a 
highly conserved molecular and cellular program that facilitates the conversion of 
epithelial cells into motile and invasive mesenchymal cells. EMT is essential 
during embryogenesis, wound healing, and contributes pathologically to fibrosis 
and cancer metastasis (Polyak and Weinberg, 2009a). Induction of EMT causes 
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epithelial cells to lose apical-basal polarity as tight junctions and cell-cell 
junctions are disassembled (Huang et al., 2012). In addition, cytoskeletal proteins 
are rearranged to achieve a front-back end polarity necessary for directional 
migration, and extracellular matrix (ECM) degrading enzymes are produced and 
secreted to destroy the underlying basement membrane (Lamouille et al., 2014). 
These changes transition an epithelial cell from a cuboidal epithelial shape to a 
more spindle mesenchymal shape and allow dissociation from neighboring cells 
and invasion into surrounding tissue (Hay, 1995).  
In addition to changes in cell shape and acquisition of motility, EMT 
promotes fundamental alterations in the gene expression profiles of cells. During 
the transdifferentiation of cells, expression of genes that mediate the epithelial 
phenotype are repressed including cytokeratins, epithelial cell polarity proteins, 
and adherens junction proteins like E-cadherin (Huang et al., 2012; Thiery and 
Sleeman, 2006). Concurrently, expression of genes mediating the mesenchymal 
phenotype is induced, including components of the mesenchymal cytoskeleton, 
vimentin, mesenchymal adherens junction proteins like N-cadherin, proteases, 
integrins, and ECM proteins (Thiery and Sleeman, 2006). The execution of EMT 
is dependent on these gene-expression changes and is highly coordinated by a 
network of intracellular and extracellular signals that converge on a set of key 
transcription factors (TF) that function as the master regulators of EMT (Kalluri 
and Weinberg, 2009). Key findings from both development and cancer have 
provided significant advances in identifying the transcription factors, adhesion 
molecules, and signaling pathways that mediate EMT (Lim and Thiery, 2012). 
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Our understanding of EMT has increased significantly and it is now clear that 
EMT programs promote cancer cell survival, stemness, inflammation, and 
immunity (Nieto, 2011). These advances have established the EMT programs as 
major therapeutic target to treat cancer.  
 
EMT in development 
EMT was initially described in early phases of embryonic development 
when tissue remodeling and cell migration are critical (Trelstad et al., 1967). 
During embryonic development, EMT is a crucial process during implantation of 
the embryo into the uterus, gastrulation to form the three germ layers, and neural 
crest (NC) formation (Lim and Thiery, 2012). The parallels between 
developmental EMT and pathogenic EMT validate the embryo as an excellent 
model to study the molecular and cellular mechanisms driving EMT. Several key 
findings from embryonic development have helped to assemble our current 
understanding of EMT and have allowed the identification of EMT programs that 
are exploited by cancer cells (Thiery et al., 2009).  
EMT is required during gastrulation when individual cells dissociate from 
the ectoderm and migrate towards the center of the embryo to form the 
mesoderm. Studies during gastrulation have identified numerous signaling 
pathways responsible for initiating EMT. Primary inducers of EMT during 
gastrulation include Wnt, fibroblast growth factor (FGF), and family members of 
transforming growth factor β (TGFβ) including Nodal, and vg1 (Heisenberg and 
Solnica-Krezel, 2008). In response to EMT inducing signals, gastrulating cells 
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upregulate the key transcription factors (TFs) Snail and Twist that function as 
repressors of E-cadherin and are required for gastrulation. Snail is part of a 
family of a DNA binding zinc finger proteins that act mainly as transcriptional 
repressors. Loss of function studies in sea urchins, flies, chicks, and mice reveal 
a highly conserved role for Snail during gastrulation (Carver et al., 2001; 
Grosshans and Wieschaus, 2000; Nieto et al., 1994; Wu et al., 2007). In all 
species tested, embryos deficient for Snail fail to gastrulate due to the inability of 
mesoderm to downregulate E-Cadherin (Carver et al., 2001; Grosshans and 
Wieschaus, 2000; Nieto et al., 1994; Wu et al., 2007). These findings underlie a 
functional role of Snail and its downstream effectors in promoting changes in cell 
shape, cell adhesion and cell movements to execute the EMT program. Further 
studies support a role for Snail in facilitating degradation of the underlying 
basement membrane by activating metalloproteases and repressing components 
of laminin to promote invasion into the ECM (Haraguchi et al., 2008; Jorda et al., 
2005).   
Twist is also a TF induced by primary EMT signals during gastrulation. 
Twist is a basic helix-loop-helix transcription factor that indirectly represses E-
cadherin and is essential for promoting EMT in invertebrates. In sea urchins, loss 
of Twist inhibits gastrulation (Wu et al., 2008). In flies, Twist orchestrates rapid 
changes in cell shape by interacting with the transmembrane protein T48 and 
recruiting Rho GTP-exchange factor and cytoskeletal remodeler, RhoGEF2, to 
adherens junctions (Kolsch et al., 2007). In vertebrates, the T48 protein is not 
conserved and Twist is not required for gastrulation, indicating that Snail may 
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compensate for Twist and accomplish all of these functions. Other critical 
repressors of E-cadherin that have been identified during gastrulation include 
p38-MAPK, p38 interacting protein (p38-IP) and the FERM (EPB4.1L5) which 
directly repress E-cadherin protein levels (Thiery et al., 2009).  
NC development represents one of the key EMT programs that occurs 
during embryonic development. NC progenitors undergo EMT from the dorsal 
neural epithelium, migrate extensively throughout the embryo and differentiate 
into a variety of cell types, including neurons and glia in the peripheral nervous 
system, connective tissue and bone that make up craniofacial structures, and 
melanocytes (Le Douarin and Kalcheim, 1999). The gene regulatory network 
(GRN) operating during neural crest EMT is induced by a number of growth 
factors that specify the neural crest territory during NC induction. The combined 
action of growth factors TGFβ, BMP, FGF and Wnt induce expression and/or 
stability of canonical EMT transcription factors Snail1/2, Twist1 and Zeb1/2 (Lee 
et al., 2013; Powell et al., 2013). However, direct evidence that any of these 
growth factors directly control EMT is lacking, and the functional loss of individual 
EMT TFs does not result in the dramatic EMT defects observed during 
gastrulation (Murray and Gridley, 2006; Tang et al., 2010). For instance, Snail is 
required for gastrulation across multiple species but in mice loss of Snail1 and 
Snail2 does not disrupt EMT and neural crest formation (Murray and Gridley, 
2006). These observations suggest that an extraordinary degree of cooperation 
and plasticity exists within the NC EMT GRN. Indeed, many regulatory loops 
among NC EMT inducers and TFs have been identified which enable 
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compensation after loss of a single regulator (Thiery and Sleeman, 2006). Our 
understanding of the GRNs operating during embryogenesis remains incomplete, 
partly due to the difficulty in labeling and observing the transient nature of EMT in 
a whole animal. Future studies will benefit from new transgenic animal models 
that label cells for visualization of EMT in vivo and isolation for genome wide 
approaches.  
The NC provides a unique opportunity to study the complexity of signaling 
networks regulating EMT as there is a close resemblance between the formation 
of the vertebrate NC and the stages of metastasis. During both processes, cells 
delaminate from the primary tissue by undergoing an epithelial-mesenchymal 
transition (EMT), actively migrate, colonize distant target sites and finally 
differentiate into a secondary tumor or a NC derivative (Theveneau and Mayor, 
2012). A more comprehensive understanding of the molecular and cellular 
regulators of NC EMT will provide insight into the developmental programs that 
can be exploited by cancer cells to promote invasion and metastasis. Not 
surprisingly genes controlling NC development are aberrantly activated during 
metastasis of several tumors including NC derived and non-NC derived tumors 
(Gupta et al., 2005; Yang et al., 2004). For this reason, the NC serves as an 
excellent model to better understand the invasion mechanisms of all cancers 
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EMT in cancer 
Local invasion is a necessary first step in metastatic dissemination; the 
induction of EMT in cancer cells enables invasive and migratory behaviors that 
contribute to this step in tumor progression (Hanahan and Weinberg, 2011). 
Carcinoma cells undergoing EMT have been observed at the invasive edge of 
primary tumors (Hlubek et al., 2007). There is a strong resemblance in the 
cellular reorganization exhibited by invasive carcinoma cells and embryonic cells 
undergoing EMT. In cancer cells loss of E-cadherin also plays a dominant role in 
influencing EMT and the malignant behavior of epithelial cancer cells. 
Inactivation of E-cadherin in cancer cells through transcriptional repression, 
promoter methylation, or functional mutations results in changes in cellular 
morphology, motility and ability to invade into surrounding tissue (Jeanes et al., 
2008). In cancer cells, active transcriptional repression of E-cadherin is achieved 
through induction of EMT-associated TFs required in embryonic development 
(Batlle et al., 2000; Cano et al., 2000; Peinado et al., 2004). For example, in 
cancer cells expression of Snail represses E-cadherin expression and induces 
EMT in epithelial tumors similar to its role in development (Batlle et al., 2000; 
Cano et al., 2000). In human tumor samples, expression of Snail and Twist 
significantly correlates with disease relapse and poor survival in patients with 
breast, colorectal, ovarian, and melanoma (Hoek et al., 2004; Puisieux et al., 
2014; Taube et al., 2010). Additionally, high expression of EMT TFs is correlated 
with high histological tumor grade and a subtype of invasive lobular breast 
carcinoma, a highly infiltrating tumor type associated with loss of E-cadherin 
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expression (Yang et al., 2004). The similarities between EMT signaling during 
embryogenesis and tumor development provide evidence that cancer cells 
reactivate developmental EMT programs in order to acquire invasive and 
migratory characteristics that promote metastatic dissemination (Gupta et al., 
2005; Yang et al., 2004).  
 
TGFB signaling   
The signaling pathways regulating EMT during cancer are not completely 
defined but are controlled by similar signaling molecules that execute EMT during 
embryogenesis. For example, TGFβ is a primary inducer of EMT in cancer cells 
and is a prerequisite for cancer cell invasion and dissemination (Katsuno et al., 
2013; Lamouille et al., 2014). Activation of TGFβ suppresses E-cadherin 
expression and induces the cellular conversion of cancer cells into a spindle cell 
shape (Portella et al., 1998). Suppression of E-cadherin in TGFβ stimulated cells 
is facilitated partly by increased expression and activity of Snail. TGFβ activates 
SMAD to induce transcription of Snail and to cooperate with Snail in a co-
repressor complex that increases Snail activity (Hoot et al., 2008; Vincent et al., 
2009). Expression and activity of other EMT TFs like Zeb and Twist are also 
induced through TGFβ in cancer cells (Kang et al., 2003; Shirakihara et al., 
2007).  TGFβ induces expression of Zeb through MAP Kinase dependent 
signaling (Shirakihara et al., 2007) and enhances activity and expression of Twist 
by indirectly repressing ID1 expression (Kang et al., 2003). Additionally, TGFβ 
can directly contribute to the disassembly of epithelial cells by inducing RHOA 
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degradation at tight junctions (Ozdamar et al., 2005) and promotes a 
mesenchymal switch by directly activating expression of mesenchymal genes like 
fibronectin and vimentin (Kaimori et al., 2007; Nawshad et al., 2007). These 
findings provide evidence that TGFβ signaling plays a central role in mediating 
EMT in cancer cells. 
Studies in cancer cells have enabled the identification of many 
downstream mediators of TGFβ signaling that are required for TGFβ-induced 
EMT. For example, signaling transduced through RHO-like GTPases, PI3K, 
mTORC, and MAPK pathways can facilitate TGFβ induced EMT (Moustakas and 
Heldin, 2005). TGFβ promotes cytoskeletal changes that enable invasion and 
motility by inducing expression of GEFs and activation of ROCK and LIMK to 
stimulate RHOA activation (Bhowmick et al., 2001; Shen et al., 2001; Vardouli et 
al., 2005). Activation of GTPases like RHOA are required in TGFβ -induced EMT 
to regulate actin dynamics and reorganization which drive formation of 
lamellipodia and filopodia that help direct motility (Ridley, 2011). Activation of the 
mTORC pathway through TGFβ induced PI3K-AKT signaling is also essential to 
promote invasion and migration of cancer cells undergoing EMT (Bakin et al., 
2000; Lamouille et al., 2012; Lamouille and Derynck, 2007). Additionally TGFβ 
can stimulate PI3K-AKT and MAPK signaling to increase expression and 
stabilization of Snail (Julien et al., 2007; Marchetti et al., 2008). These studies 
highlight the ability of TGFβ to activate several pathways and suggest the 
existence of signaling cooperation and convergence of these pathways on 
common EMT targets. It should be noted that the downstream mediators of 
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TGFβ have mainly been identified from studies in cell culture and further work is 
required to test the necessity of these signals in vivo. In the future, 
complementary in vivo approaches that allow labeling and observation of EMT in 
living animals are needed to identify effective inducers of EMT in vivo.  
 
MicroRNAs   
The advancement of novel molecular mechanisms regulating EMT has 
been facilitated by studies in cancer research. Among these, microRNAs have 
emerged as important inducers and suppressors of the EMT program. For 
example, miR-1 and miR-200 directly suppress EMT by inhibiting Snail 
expression and the miR-200 family along with miR-205 function similarly by 
repressing expression of Zeb (Gregory et al., 2008; Liu et al., 2013). Additional 
microRNAs that induce EMT have also been identified, such  as miR-9, which 
directly suppresses E-cadherin expression (Ma et al., 2010). These studies 
illustrate the crucial role of microRNAs in dictating the progression of EMT. 
 
Alternative splicing 
Intriguingly, extensive changes in splicing patterns have been documented 
to accompany the transdifferentiation of epithelial cells into mesenchymal cells. 
Several studies show that primary inducers of EMT can promote a shift in 
splicing patterns and highlight a key role of splicing mediators in controlling EMT 
(Shapiro et al., 2011; Shirakihara et al., 2011). The importance of alternative 
splicing in EMT has been demonstrated by epithelial splicing variant 1 and 2 
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(ESPR1 and ESPR2), which mediate a splicing program that is suppressed 
during EMT (Taube et al., 2010; Warzecha et al., 2010). Together, these studies 
established alternative splicing as a novel mechanism to control EMT. 
 
Epigenetic regulators 
Epigenetic control of EMT has also been implicated as a novel mechanism 
in cancer cells. Aberrant DNA methylation patterns affecting EMT inducers and 
effectors during carcinoma progression have been identified in a mouse model of 
skin carcinogenesis (Fraga et al., 2004). Epigenetic modification by SIN3A, a 
histone deacetylase, promotes EMT by cooperating with Snail to repress E-
cadherin expression (Herranz et al., 2008; Peinado et al., 2004). In contrast, 
epigenetic modifiers also inhibit EMT and cancer invasion by repressing Snail 
expression (Fujita et al., 2003). These studies provide new insights into the 
diverse molecular mechanisms regulating EMT and add a new level of regulation 
between the epithelial and mesenchymal states. 
 
RTK signaling 
Induction of EMT can also be accomplished by activation of receptor 
tyrosine kinases (RTKs). Similar to TGFβ signaling, RTKs can induce EMT by 
stimulating the activation of multiple signaling pathways including PI3K-AKT, 
MAPK, and JNK pathways (Lamouille et al., 2014). Numerous RTKs activate 
EMT in cancer cell lines, which highlight the importance of the downstream signal 
transducers PI3K and MAPK in the regulation of EMT. For example, c-MET RTK 
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can stimulate the induction of EMT through increasing expression of Snail 
(Doehn et al., 2009). The induction of Snail expression by c-MET requires 
activation of a key effector of the MAPK pathway (Doehn et al., 2009). Activating 
oncogenic mutations in RAF and RAS also induce EMT by stabilizing Snail 
proteins and RHO-GTPases, which further supports the role of MAPK signaling 
in promoting motile and invasive behavior of carcinoma cells (Makrodouli et al., 
2011). Remarkably, the intracellular signals stimulated by most RTKs converge 
on the induction and activation of EMT TFs and repression of epithelial adhesion 
junctions. Such is the case for fibroblast growth factor receptor (FGFR), which 
induces EMT in cancer cells by dissociating desmosomes and promoting 
expression of Snail (Billottet et al., 2008; Savagner et al., 1997; Valles et al., 
1996). In colon adenocarcinomas, platelet-derived growth factor receptor 
(PDGFR) induces EMT through the dissolution of adherens junctions, which 
promotes the nuclear translocation of β-catenin through a WNT-independent 
pathway (Yang et al., 2006). Additionally, epidermal growth factor receptor 
(EGFR) can promote EMT by inducing endocytosis of E-cadherin and expression 
of Snail and Twist (Lo et al., 2007; Lu et al., 2003). 
Together, the studies described above emphasize the diversity of signals 
that promote EMT and demonstrate that an intricate network of signals work in 
parallel to activate common EMT targets. Furthermore, these findings provide 
rational therapeutic targets that can be investigated as antimetastatic agents.  
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AXL signaling in EMT and cancer 
The RTK AXL has been implicated in EMT induction and is currently being 
investigated as a therapeutic target for the treatment of metastatic cancers 
(Gjerdrum et al., 2010; Linger et al., 2010). AXL is part of the TAM (Tyro3, Axl, 
Mer) family of RTKs characterized by an adhesion molecule-like domain in the 
extracellular region that consists of two fibronectin type 3 motifs and two 
immunoglobulinlike repeats. Activation of AXL by its ligand Gas6 or AXL 
overexpression stimulates several signaling pathways including PI3K-AKT, 
mTORC, NF-kB, STAT3 and MAPK signaling (Hafizi and Dahlback, 2006). AXL 
regulates a variety of cellular processes including cell proliferation, cell survival, 
cell adhesion and migration (Linger et al., 2008). Overexpression of AXL has 
been reported in several types of leukemias and solid tumors and its expression 
independently predicts poor prognosis in several cancers (Linger et al., 2008). 
Several studies have demonstrated that AXL signaling contributes to cancer 
progression by mediating cell survival, invasion, migration, metastasis and 
resistance to standard chemotherapies and RTK inhibitors (Linger et al., 2010).  
Recent studies have revealed that AXL can induce EMT in vitro and is 
highly associated with the mesenchymal phenotype in human cancer cells 
(Asiedu et al., 2014; Gjerdrum et al., 2010; Wilson et al., 2014). Induction of EMT 
by overexpressing EMT TFs Twist, Zeb2, Snail, and Slug increases expression 
and activation of AXL, which promotes EMT-associated cytoskeletal and 
morphological changes (Gjerdrum et al., 2010; Holland et al., 2010). 
Interestingly, AXL expression is required to maintain Snail, Slug, and Twist 
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expression in pancreatic adenocarcinoma cells (Koorstra et al., 2009).  Together 
these studies indicate that AXL is involved in a positive feedback loop that 
promotes and sustains the mesenchymal phenotype of cancer cells. Additionally, 
activation of AXL in cancer cells induces a cancer stem cell phenotype, regulates 
self-renewal, and resistance to chemotherapies and receptor tyrosine kinase 
inhibitors (Asiedu et al., 2014; Byers et al., 2013; Wilson et al., 2014).  Future 
studies will help elucidate the AXL-dependent signaling pathways driving EMT, 
self-renewal and resistance to therapy.  
 
EMT-induced formation of CSCs 
  It is becoming increasingly clear that the induction of EMT can generate 
cancer stem cells (CSCs). CSCs generated through EMT are capable of initiating 
tumor formation, self-renewing, and contribute to metastases and resistance to 
conventional therapies (Singh and Settleman, 2010). The first direct link between 
EMT and gain of epithelial stem cell properties was provided by Mani and 
colleagues (Mani et al., 2008), who demonstrated that induction of EMT in 
normal and malignant mammary epithelial cells resulted in the acquisition of 
stem-cell-like characteristics. Several studies have provided additional evidence 
that highly aggressive and undifferentiated tumors have both EMT and stem cell 
characteristics (Ben-Porath et al., 2008; Hennessy et al., 2009; Sarrio et al., 
2008; Taube et al., 2010). Mesenchymal cells and CSCs generated from an EMT 
are highly resistant to therapies (Creighton et al., 2009; Shintani et al., 2011; 
Thomson et al., 2005). This was highlighted in a study by Creighton et al., who 
	   16	  
demonstrated that residual tumor cells surviving after conventional chemotherapy 
treatment were enriched with EMT and stem cell markers (Creighton et al., 
2009). Consistent with this, induction of EMT in cancer cells promotes resistance 
to chemotherapies and RTK inhibitors (Shintani et al., 2011; Thomson et al., 
2005; Thomson et al., 2008). These studies provide evidence that EMT mediates 
self-renewal of cancer cells and response to chemotherapies and targeted 
therapies. 
 
Targeting EMT in cancer 
Induction of EMT in human cancer cells promotes survival and self-
renewal (Mani et al., 2008; Polyak and Weinberg, 2009b) and confers the ability 
to migrate, survive and self-renew in foreign environments, all essential 
requirements for metastatic behavior. Several strategies for targeting the EMT 
pathways are being investigated to control cancer cell invasion, self-renewal, and 
metastatic dissemination (Davis et al., 2014). Approaches to target EMT involve 
inhibiting the induction of EMT through targeting extracellular signals as well as 
targeting critical intracellular signal transduction pathways. The preferred strategy 
to target the induction of EMT has been through the suppression of RTK 
signaling using receptor antagonists, antibody inhibitors or small molecule 
inhibitors. Examples of RTK inhibitors identified to inhibit EMT induction in vitro 
include EGF receptor tyrosine kinase inhibitor AG1487 and TGFβ receptor 
kinase inhibitor SB431542 (Halder et al., 2005; Lo et al., 2007). Other inhibitors 
that have been validated to inhibit EMT in cancer cell lines include AXL inhibitor 
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R428 (Holland et al., 2010), c-Met inhibitor SU11274 (Toiyama et al., 2012), and 
IGF1R inhibitor AG1024 (Vazquez-Martin et al., 2013). Although these studies 
provided important preliminary evidence supporting the clinical development of 
EMT inhibitors, there are limitations to the homogeneous cell culture technique 
used in these studies as they do not replicate the tissue interactions and 
numerous microenvironment signals present in normal physiological conditions 
as cells are undergoing EMT. Complementary in vivo approaches are required to 
validate the efficacy of these inhibitors.    
 Another valid approach to inhibiting EMT is to target the critical 
intracellular signaling transduction pathways. Recent advances in the generation 
of small molecule inhibitors targeting transcription factors (Siddiquee et al., 2007) 
has provided a potential strategy to develop novel ways of targeting of EMT-
associated TFs such as Snail, Slug, Zeb, and Twist to block EMT. The 
effectiveness of targeting Snail family members to inhibit EMT during both 
development and cancer progression has already been established (Cano et al., 
2000; Carver et al., 2001; Kudo-Saito et al., 2009; Peinado et al., 2004; Vincent 
et al., 2009), which supports the notion to target EMT TF as a therapeutic 
strategy. 
Another approach currently being explored is targeting the mesenchymal 
phenotype. Proteins that make up the mesenchymal phenotype like vimentin, 
matrix metalloprotease enzymes, and fibronectin proteins are currently being 
investigated as therapeutic targets (Davis et al., 2014). A bioactive compound 
called Withaferin-A has been shown to inhibit the intermediate filament protein 
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Vimentin, block cell invasion and migration of cancer cells in vitro and suppress 
metastasis in xenograft tumor models (Lahat et al., 2010; Thaiparambil et al., 
2011). Methods to target CSCs generated from an EMT are also being 
investigated. Monoclonal antibodies targeting CD44, a cell surface marker of 
CSCs, are currently under development (Marangoni et al., 2009). Additionally, 
the identification of the potassium ionophore Salinomycin as a selective inhibitor 
of CSCs generated by EMT induction has demonstrated promising results as it 
has significant toxicity against CSCs (Gupta et al., 2009). Further studies are 
required to identify the efficacy of Salinomycin in vivo and to determine its effect 
on normal adult stem cells.   
The pharmacological targets identified so far all have implications in cell 
signaling that go beyond regulating EMT and should be considered carefully to 
avoid severe toxicity in cancer patients. Furthermore, inhibitors of EMT induction 
may only be effective as an adjuvant therapy to prevent metastasis and eradicate 
residual tumor cells and prevent tumor reoccurrence. Treating patients who have 
pre-existing metastasis with inhibitors of EMT or the mesenchymal phenotype 
may accelerate epithelialization of disseminated mesenchymal cells or promote 
the formation of more metastases. Only comprehensive in vivo experimental 
approaches will help determine the most effective inhibitors of EMT, stemness, 
and therapeutic resistance. 
While identifying inhibitors of EMT is of great therapeutic interest there are 
currently no effective EMT inhibitors in the clinic. This is due to both our 
incomplete understanding of EMT, and the difficulty in modeling the physiological 
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complexity of EMT in cell culture systems (Davis et al., 2014). Additionally, 
complementary in vivo approaches to identify effective EMT inhibitors have been 
limited by the difficulty in labeling and observing EMT in a living animal. In my 
graduate studies we have overcome this challenge by developing a zebrafish in 
vivo EMT reporter and implemented it in a chemical genetic screen to identify 
small molecules inhibitors of EMT (Chapter 2). Through our studies we identified 
a potent small molecule inhibitor of EMT, called TP-0903, that functions by 
increasing retinoic acid signaling to block EMT during development. Additionally 
our findings provided insight into candidate signaling pathways, like AXL RTK, 
that could be tested for promoting cancer cell invasion in vivo using an 
established zebrafish melanoma model (Chapter 3). These studies present the 
first animal model that can be used to identify effective small molecule inhibitors 
of EMT in vivo and novel signaling pathways regulating cancer progression to 
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Abstract 
The epithelial to mesenchymal transition (EMT) is a highly conserved 
morphogenetic program essential for embryogenesis, regeneration and cancer 
metastasis. In cancer cells, EMT also triggers cellular reprogramming and 
resistance to chemotherapy, which underlie disease relapse and decreased 
survival. Hence, identifying compounds that block EMT is essential to prevent or 
eradicate disseminated tumor cells. Here, we establish a novel in vivo EMT 
reporter in zebrafish for rapid drug screening called Tg(snai1b:GFP), which 
labels Snail1-expressing cells undergoing EMT during development, including 
dorsal neural tube progenitors that form neural crest. Treating Tg(snai1b:GFP) 
embryos with small molecule compounds identified a multi-kinase inhibitor TP-
0903, which inhibited neuroepithelial EMT. RNA-Seq analysis and chemical 
rescue experiments show TP-0903 acts through activation of retinoic acid (RA) 
biosynthesis and signaling. These studies identify TP-0903 as a new therapeutic 
for activating RA in vivo and indicate the previous enigmatic success of RA in 
eliminating disseminated cancer cells is through inhibition of EMT.  
 
Resource impact 
Induction of the Epithelial to Mesenchymal Transition (EMT) in cancer 
cells promotes acquisition of invasive cellular morphologies, stem-cell-like 
properties and prosurvival mechanisms that contribute to therapeutic resistance, 
relapse and decreased overall survival. Identifying EMT inhibitors for clinical use 
is of great therapeutic interest as adjuvant therapies to eliminate rare or dormant 
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cells, but no effective EMT small molecule compounds have yet entered the 
clinic. This is due to an incomplete understanding of the molecular mechanisms 
regulating EMT in both normal development and disease. In addition, a number 
of compounds that inhibit EMT in vitro fail to inhibit EMT in vivo, due to the fact 
that 1) cell culture assays do not mimic the complexity of the normal 
physiological or disease environments and 2) multiple compensatory pathways 
likely function in parallel to induce EMT in vivo. Clearly complementary in vivo 
approaches are needed to screen and identify effective EMT inhibitors. 
Unfortunately, difficulty in labeling and observing EMT in living animals in large 
numbers for screening has prevented us from using such approaches. 
In this study, we have overcome this roadblock and developed a zebrafish 
in vivo EMT reporter to rapidly screen small molecules for their ability to inhibit 
EMT. We identified a novel small molecule EMT inhibitor, called TP-0903, that 
potently inhibits EMT in vivo, and determined its mechanism of action in this 
process through promoting retinoic acid (RA) biosynthesis. We also show for the 
first time that RA itself inhibits EMT (despite numerous studies showing RA 
affects other aspects of neural development). These results may explain the 
previous enigmatic ability of RA as a successful adjuvant therapy to eradicate 
minimal residue disease and improve cancer patient survival. We also discuss 
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Introduction 
The conversion of epithelial cells into migratory, invasive mesenchymal 
cells is a fundamental morphogenetic process during development and 
regeneration. Induction of epithelial-mesenchymal transition (EMT) causes 
epithelial cells to lose intracellular junctions, apical-basal polarity and gain 
cytoskeleton reorganization that is prerequisite for motility and invasion through 
surrounding tissue (Hay, 1995). In addition, several studies have demonstrated 
that reactivation of developmental EMT programs in cancer cells constitutes a 
key step during metastasis (Thiery et al., 2009). EMT can award cancer cells with 
invasive properties to allow dissemination from the primary tumor and promote 
the acquisition of stem cell like properties (Mani et al., 2008), therapeutic 
resistance (Kurrey et al., 2009; Li et al., 2009), increased survival and immune-
suppression (Polyak and Weinberg, 2009), all of which contribute to poor patient 
prognosis. For these reasons targeting EMT in cancer patients has gained 
significant therapeutic interest. 
Our understanding of the cellular and molecular pathways controlling EMT 
in normal or cancerous cells remains incomplete, hindering efforts to rationally 
target EMT in the clinic. Indeed, most current small molecule EMT inhibitors were 
discovered through unbiased cell-based in vitro screening techniques (Davis et 
al., 2014). However, these assays are usually restricted to single homogeneous 
cell types and do not fully recapitulate the complex physiological environment in 
which other cell types and different extracellular matrix (ECM) components 
impact EMT induction. Establishing in vivo EMT reporter assays for rapid 
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screening is essential to complement conventional cell-based assays to identify 
the most effective EMT inhibitors for human disease. In addition, whole animal–
based EMT reporter models allow direct assessment of compounds on normal 
cell populations to determine tissue-specific toxicities, as well as discovery of 
novel molecular pathways controlling physiological EMT that can be rationally 
targeted. 
 The embryonic dorsal neural tube of vertebrates is an excellent system to 
identify mechanisms controlling EMT because these cells undergo highly 
predictable EMT movements to form migratory neural crest (NC) cells that then 
migrate collectively or individually to generate a variety of cell types, such as 
cardiac, craniofacial, and pigment cells, as well as neurons and glia of the 
peripheral nervous system (Green et al., 2015). Thus, defects in dorsal neural 
tube EMT and NC migration underlie a number of human congenital diseases, 
particularly craniofacial abnormalities. NC-derived lineages are also the origin of 
some of the most highly metastatic human cancers, such as melanoma and 
neuroblastoma, suggesting these cancers can readily reprogram their embryonic 
EMT and cell migration mechanisms to promote rapid tumor dissemination. 
Indeed, seminal work that originally linked EMT to cancer metastasis showed 
genes expressed during neural tube EMT are aberrantly activated during 
metastasis (Gupta and Massague, 2006; Kang and Massague, 2004; Yang et al., 
2004). Among these are members of the Snail and Twist family of transcription 
factor genes, which repress the expression of epithelial cell adhesion molecules, 
including E-cadherin, to promote EMT during both development and in metastatic 
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tumors (Gupta et al., 2005). This suggests that inhibitors of conserved signaling 
pathways controlling dorsal neural tube EMT will also be excellent therapies for 
blocking EMT during tumor invasion and/or metastasis.  
Based on numerous studies in different vertebrate species, current models 
suggest that EMT in the dorsal neuroepithelium is induced by the combined 
actions of a number of growth factors secreted from the epiblast (BMP 
antagonists), underlying paraxial mesoderm (FGF) and ectoderm (Wnt). These 
pathways converge at the epithelial neural folds to induce the expression of 
canonical EMT transcription factors, such as Snail1/2, Twist1 and Zeb1/2, as well 
as NC “specifier” genes Sox9/10, Foxd3 and tfAP2α (Knecht and Bronner-
Fraser, 2002; Sauka-Spengler and Bronner-Fraser, 2008). Thus, a gene 
regulatory network, mediated primarily through TGFb/BMP and Wnt signaling, is 
proposed to control Snail1/2 and Twist1 expression and/or stability, which in turn 
promotes EMT to produce NC cells expressing NC specifier genes. However, 
there is no direct evidence that any of the above growth factors directly control 
EMT. Indeed, to our knowledge, there are no examples in which a single 
pathway can inhibit EMT within the neural tube to cause neuroepithelial 
progenitors to remain trapped within the neural tube. This suggests multiple 
compensatory mechanisms control NC EMT at the level of extracellular signaling, 
transcription factor expression/regulation or both. Identifying the essential, non-
redundant signaling pathways required for EMT in vivo, or combinations, will be 
essential to understand normal NC development and allow us to rationally target 
and inhibit EMT during cancer progression. 
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Here we develop a novel zebrafish EMT reporter called Tg(snai1b:GFP) 
that fluorescently labels dorsal neural tube progenitors undergoing EMT. In 
contrast to previous NC reporters in zebrafish, the Tg(snai1b:GFP) reporter 
labels the earliest progenitor population of dorsal neural tube cells before NC 
specifier genes are expressed and without the need for sophisticated confocal 
imaging. In addition, thousands of Tg(snai1b:GFP) embryos can be generated 
per day by simple genetic crosses for rapid screening, without the need to 
manually inject DNA constructs into every embryo (Berndt et al., 2008). Indeed, 
by combining the Tg(snai1b:GFP) neuroepithelial lineage marker with the 
previously established NC reporter, Tg(sox10:RFP), we show only 
Tg(snai1b:GFP) labels delaminating dorsal neural tube cells and directly observe 
the birth of Sox10-positive NC cells from delaminating dorsal neural tube 
progenitors. We also demonstrate that Tg(snai1b:GFP) is readily amenable to 
chemical genetic screening and identified a novel multi-kinase inhibitor, called 
TP-0903 that potently blocks EMT and cell migration. Genomic analysis and 
chemical rescue experiments showed TP-0903 activates RA signaling by 
increasing biosynthesis. Our findings reveal unexpected and previously 
unrecognized roles for RA in inhibiting EMT during NC development, and 
suggest activation of RA signaling through TP-0903 represents a new therapeutic 
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Results 
Generation of the EMT reporter line: Tg(snai1b:GFP) 
Snail transcription factors are inducers of EMT in a number of cell 
populations during metazoan development (Nieto, 2002). The snai1b gene is 
expressed during early gastrulation in nascent mesodermal cells, in 
neuroepithelial cells within the neural keel, at the neural plate border and in pre- 
and postmigratory NC (Figure 2.1A). To directly visualize dorsal neural tube EMT 
behaviors we isolated and subcloned approximately 3-kb of the snai1b promoter 
into a modified pEGFP-1 plasmid and generated a transgenic strain called 
Tg(snai1b:GFP) (see Methods). Examination of GFP expression in other tissues 
showed Tg(snai1b:GFP) also labels cells during gastrulation and segmentation 
stages, such as the involuting mesendoderm and somites (Figure 2.2), which 
express endogenous snai1b and undergo EMT, but were not examined further in 
this study. 
To verify the Tg(snai1b:GFP) line recapitulates endogenous snail1b 
mRNA expression, we compared the fluorescent GFP pattern in Tg(snai1b:GFP) 
embryos to snail1b mRNA in situ hybridization at various development stages 
(Figure 2.1A). At 15 hours postfertilization (hpf), Tg(snai1b:GFP) embryos 
express GFP in neuroepithelial and neural plate border cells, consistent with the 
expression pattern of endogenous snail1b mRNA (Figures 2.1A and Movie S1). 
At 16.5 hpf, when all cranial NC streams have begun to migrate, GFP-positive 
cells appear in NC streams. This trend continues at 18 hpf, with GFP expression 
most prominent in the first and second cranial NC streams and most anterior 
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neuroepithelium, while there is comparatively less GFP expression in the vagal 
NC stream, similar to the endogenous snai1b mRNA pattern. At 24 hpf, GFP 
expression is diminished in most cranial NC cells and instead is expressed in 
delaminating trunk cells (Figure 2.1B) and other cells types (Figure 2.2). 
Previous studies demonstrate the sox10 promoter labels NC cells 
undergoing delamination behaviors (Berndt et al., 2008). To determine if 
Tg(snai1b:GFP) embryos express GFP in the same neuroepithelial cells as 
sox10, we generated double transgenic Tg(snai1b:GFP); Tg(sox10:RFP) animals 
and analyzed EMT by two color confocal time-lapse imaging during cranial NC 
development (Movie S2). Unexpectedly, we found only Tg(snai1b:GFP) readily 
labeled dorsal neuroepithelial cells from 15- to 18-hpf (Figure 2.1A), while 
Tg(sox10:RFP) more robustly labeled premigratory NC at the lateral neural plate 
border and migrating NC cells (Figure 2.1A), with some overlap between the two 
transgenes in this population. Thus, the Tg(snai1b:GFP) transgenic line allows 
direct visualization of all neuroepithelial progenitors within the neural tube that 
are predicted to undergo EMT to form NC, while sox10-driven transgenes 
preferentially labels pre- and postmigrating NC. 
 
Visualization of EMT in Tg(snai1b:GFP) animals 
Our comparative study of snai1b- versus sox10-promoter driven 
expression suggest the snai1b promoter readily labels dorsal neuroepithelial cells 
with potential to undergo EMT (and not the entire neuroepithelium). To confirm 
this, we analyzed transverse sections through the hindbrain region of double 
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transgenic Tg(snai1b:GFP); Tg(sox10:RFP) animals at different developmental 
stages (Figure 2.3A). During the neural rod stage (15 hpf), GFP is expressed in 
distinct two locations, the dorsal half of the neural rod and cells adjacent to the 
neural plate border, while sox10-driven mRFP is expressed in cells adjacent to 
the neural plate border (Figure 2.3A). During the neural tube stage (18 hpf), GFP 
expression was further restricted to the dorsal most region of the neural tube and 
is gradually diminished once cells emerge from the neural tube, labeling only a 
subset of sox10-positive migratory NC cells. In contrast, sox10-driven RFP was 
expressed in pre- and postmigratory NC at 18 hpf, but still absent from the dorsal 
neural tube (Figure 2.3A).  
The dorsal and transverse views of Tg(snai1b:GFP) animals suggest the 
GFP-positive cells within the dorsal neural tube are fated to undergo an EMT and 
become NC cells. To confirm this, we first analyzed the expression of E-cadherin 
protein in transverse views of Tg(snai1b:GFP) animals, whose loss is a hallmark 
of EMT and show that dorsally-restricted GFP-positive cells express reduced 
levels of E-cadherin compared to the rest of the neural tube (Figure 2.3B). We 
next analyzed time-lapse recordings of double transgenic Tg(snai1b:GFP); 
Tg(sox10:RFP) animals to follow individual cell behaviors as they emerge from 
the neural tube (Figure 2.3C and Movie S3). Confocal time-lapse analysis 
confirmed that GFP-positive neuroepithelial cells in Tg(snai1b:GFP) animals 
exhibit stereotypical EMT behaviors (Figure 2.3C). Subsets of neuroepithelial 
cells contact the apical midline and basal surface. As cells initiate EMT they 
detach from the apical midline by down-regulating adherence junction and retract 
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their apical tail. Subsequently, epithelial cells round up near the basal surface 
and use blebbing motility to translocate out of the neural tube, ultimately gaining 
directed motility away form the neural tube (Figure 2.3C schematic). These 
cellular behaviors are consistent with previous live imaging studies of 
neuroepithelial cells undergoing EMT (Berndt et al., 2008; Clay and Halloran, 
2013). Confocal time-lapse analysis of the dorsal midline in Tg(snai1b:GFP); 
Tg(sox10:RFP) animals revealed novel cellular behaviors of the dorsal-most 
neural tube cells at later stages (Figure 2.4 and Movie S4), which span across 
the apical midline to contact both sides of the neuroepithelium. During 
delamination, these cells retract from both sides of the neuroepithelium 
simultaneously and lose polarity to become rounded. Subsequently, these cells 
flatten and extend cellular protrusions, such as filopodia and blebs, and begin to 
express the NC marker sox10:RFP (Figure 2.4). These studies show that the 
Tg(snai1b:GFP) line labels multiple delaminating populations of neuroepithelial 
cells that become NC, and represents a novel whole-animal EMT reporter line 
that can be used for chemical screening. 
 
Chemical screening approach to identify EMT Inhibitors 
in vivo 
Genetic crosses of the Tg(snai1b:GFP) line generate thousands of 
embryos per day, allowing rapid and direct visualization of EMT behaviors in vivo 
after genetic or chemical perturbations. To determine if the Tg(snai1b:GFP) line 
could be used to identify compounds that block NC EMT in vivo, we performed a 
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chemical screen. Tg(snai1b:GFP) embryos were treated with different doses of 
kinase inhibitors (ranging from 0.1 to 100mM) at the 3- to 8-somite stage (~13 
hpf), a time point that 1) avoids developmental delays due to interfering with 
gastrulation movements and 2) allows growth factor induction to occur at the 
neural plate border to induce EMT factors, but precedes the onset of most cranial 
neural tube EMT. Embryos were treated for 6-12 hours (hrs) and then visualized 
for GFP fluorescence in the neural tube (see Methods and Figure 2.5). Failure of 
cells to undergo EMT and migrate out of the neuroepithelium was indicated by an 
increased number of GFP-positive cells within the dorsal neural tube. 
Surprisingly, under our assay conditions, most chemical compounds did not 
cause overt EMT phenotypes in vivo (Table 2.1), including targeting common 
kinase and cytoskeletal remodeling pathways, such as the Mapk/Erk, Pi3k/Akt 
and Rho GTPase pathways, despite these pathway inhibitors having inhibitory 
EMT effects on individual cells in vitro (Berndt et al., 2008; Irie et al., 2005; 
Zheng et al., 2013). These results suggest that multiple signaling pathways may 
compensate for each other to drive the EMT program during NC development 
(see Discussion). 
Compounds that primarily target one major signaling pathway did not 
show a significant effect on NC EMT. However, a multi-kinase inhibitor called TP-
0903 (formerly known as HCI-2084) (Mollard et al., 2011) dramatically blocked 
EMT and NC cell migration (Figure 2.6). TP-0903 was rationally designed to 
target AXL RTK (IC50 = 27 nmol/L), a key oncogenic target that promotes EMT 
and metastasis (Gjerdrum et al., 2010). TP-0903 also displays strong activity 
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against 11 other kinases including Aurora A, Jak2, Alk, and Abl and is currently in 
preclinical development (Tolero Pharmaceuticals, 2015). Confocal time-lapse 
analysis of Tg(snai1b:GFP) embryos treated with TP-0903 between 11- to 19-hpf 
showed significant accumulation of GFP-positive cells within the developing 
neuroepithelium (Figure 2.6A, compare Movie S5 and Movie S6). In addition, TP-
0903 treatment of Tg(snai1b:GFP) embryos halted migration of NC cells that had 
already exited the neural tube and fused the first two cranial NC streams together 
(Figure 2.6A). Analysis of developmental timing using the lens placode or other 
NC-derived tissues (such as pigment) showed that these tissues developed 
normally, suggesting TP-0903 phenotypes did not cause a general 
developmental arrest (data not shown, also see Figure 2.8). 
To confirm TP-0903 treatment inhibited EMT we analyzed cross sections 
of Tg(snai1b:GFP); Tg(sox10:RFP) embryos treated with TP-0903 and DMSO. In 
DMSO treated embryos, the majority of the GFP-positive cells have delaminated 
from the neural tube by 24 hpf to form sox10-positive NC. In contrast, TP-0903-
treated embryos retained GFP-positive progenitor cells in the dorsal neural tube 
(Figure 2.6B). Analysis of pan-Cadherin expression in the TP-0903-treated 
embryos showed that GFP-positive cells expressed elevated Cadherin levels 
compared to DMSO-treated controls (Figure 2.6C). Finally, to determine if TP-
0903 directly affects the expression of canonical EMT transcription factors we 
analyzed expression of the Snail, Twist and Zeb by RNA in situ hybridization 
(Figure 2.6D). We found TP-0903 caused a complete loss of twist1a expression 
in cranial NC at 18 hpf, while the expression of other EMT transcription factors 
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was not significantly affected (Figure 2.6D and data not shown). Thus, the 
Tg(snai1b:GFP) transgenic strain is an effective whole-animal based model for 
identifying novel EMT and cell migration inhibitors, and identifies TP-0903 as a 
potent EMT inhibitor in vivo. 
 
TP-0903 induces a rapid retinoic acid transcriptional response 
The loss of EMT transcription factor expression, such as twist1a, 
suggested TP-0903 acts through transcriptional regulation. Therefore, we 
performed RNA-Seq analysis on control and TP-0903 treated embryos at 
different time points to determine if TP-0903 elicits an immediate or delayed 
transcriptional response. We treated zebrafish embryos with TP-0903 or DMSO 
at the 8-somite stage (13 hpf) when the brain primordium has thickened into the 
neural keel and cranial neuroepithelial cells are actively undergoing EMT. 
Embryos were treated for 1-, 4- or 8-hrs and subsequently divided into two 
groups to 1) extract RNA for gene expression analysis or 2) fixed for in situ 
hybridization to confirm differential expression of candidate genes identified from 
RNA-Seq in TP-0903 treated embryos (Figure 2.7). Analysis of the relative 
expression levels of transcripts in TP-0903- and DMSO-treated embryos at 
different time-points showed TP-0903 induces a rapid transcriptional response in 
embryos after just 1 hr, which becomes more robust by 4-hrs post-treatment. 
Analysis of differentially expressed transcripts at 1- and 4-hrs identified several 
retinoic acid (RA)-target genes, including genes from within the retinoid pathway 
itself, such as rxrga, dhrs3a/3b, and cyp26a1 and members of the Hox gene 
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family that harbor retinoic acid response elements (RARE), including hoxb1a, 
hoxb5b and hoxa4a (Figure 2.7A). Ingenuity Pathway Analysis confirmed that 
TP-0903 activates an RA transcriptional response in embryos (Figure 2.7B). To 
validate our findings we examined the expression of two differentially expressed 
genes, cyp26a1 and hoxb1a, by whole mount in situ hybridization in TP-0903 
treated embryos (Figure 2.7C). Both cyp26a1 and hoxb1a are direct 
transcriptional targets of RA and cyp26a1 is commonly used to report RA activity. 
Our in situ hybridization analysis confirmed the RNA-Seq results and showed 
that the intensity of cyp26a1 and hoxb1a expression was increased in TP-0903 
treated embryos compared to controls at 16 hpf (Figure 2.7C). We also treated 
embryos with RA at the 8-somite stage (13 hpf) and found it mimicked TP-0903 
treatment with respect to increased cyp26a1 and hoxb1a expression, although 
with a much more elevated response (Figure 2.7D).  
TP-0903 treatment induces an RA-like response, so we next analyzed the 
expression pattern of NC genes previously shown to be affected by RA treatment 
(Ellies et al., 1997; Lee et al., 1995; Matt et al., 2003). We analyzed the 
expression of dlx2a in TP-0903 treated embryos and found that it was inhibited, 
showing TP-0903, like RA itself, blocks ectomesenchymal differentiation of NC 
cells (Figure 2.8A). To determine the fate of these cells, we performed in situ 
hybridization analysis with the pan-NC marker crestin, which showed the stalled 
cranial NC cells in TP-0903 embryos were present but fused together, as 
observed in the sox10-RFP analysis (Figure 2.8B). To determine the fate of 
these cells, we analyzed NC lineage markers and found they differentiate into 
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mitfa-positive melanocyte precursors (Figure 2.8C). Consistent with this, analysis 
of mature melanophores at 48 hpf showed that TP-0903 caused the 
accumulation of pigment cells along the dorsal neural tube (Figure 2.8D). 
Together, these results show that TP-0903 causes a specific and rapid increase 
in RA-dependent transcription during NC development, which in turn inhibits both 
EMT and cell migration, and causes NC cells to adopt a nonectomesenchymal 
fate at the expense of ectomesenchymal cells. 
To directly test if TP-0903 acts through RA signaling we inhibited RA 
synthesis in TP-0903 treated embryos by co-treating Tg(snai1b:GFP); 
Tg(sox10:RFP) embryos with TP-0903 and Diethylaminobenzaldehyde (DEAB), 
a potent inhibitor of retinaldehyde dehydrogenase (RALDH), the rate-limiting 
enzyme required for the final conversion of retinal to RA. Inhibition of RA 
synthesis by DEAB in TP-0903 treated embryos rescues the NC EMT and cell 
migration defects (Figure 2.9A and compare Movies S2, S7 and S8). Co-
treatment of TP-0903 and DEAB also rescues twist1a and dlx2a expression and 
pigment differentiation defects caused by TP-0903 treatment (Figure 2.9C and 
2.9D). As expected, DEAB did not rescue RA treated embryos because 
exogenous RA treatment bypasses the need for Raldh2 and retinal conversion 
(Figure 2.9A and Movie S9 9). These results confirm that the multi-kinase 
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Retinoic acid controls cranial NC EMT, cell migration, and  
ectomesenchymal differentiation  
 The genomic, molecular and cellular analysis of TP-0903 treated embryos 
shows potential new roles for RA signaling in dorsal neural tube EMT.  To directly 
test if RA itself could inhibit EMT, we treated 3-somite stage (11.5 hpf) 
Tg(snai1b:GFP); Tg(sox10:RFP) embryos with RA and found it causes an 
accumulation of GFP-positive cells in the neuroepithelium and RFP-positive NC 
cells along the neural plate border, mimicking the TP-0903 treatment (Figure 
2.9A and 2.9B; and Movie S10 10). Additionally, we also found RA treatment 
inhibits expression of EMT regulator twist1a, chondrogenic differentiation marker 
dlx2a, and causes an accumulation of pigment cells on the neural tube at 48hpf 
(Figure 2.9C and 2.9D). These results demonstrate that increased RA is 
sufficient to impair NC EMT, cell migration and differentiation and indicate the NC 
phenotypes observed in TP-0903 treated embryos act through increasing RA 
signaling. Thus, retinoic acid signaling controls multiple events during cranial 
neural tube development; 1) delamination of NC progenitors within the neural 
tube, 2) collective cell migration away from the neural tube, and 3) differentiation 
of ectomesenchymal progenitors. While some of these RA-dependent 
phenotypes have been observed previously during NC development, these data 
are the first to show RA directly inhibits EMT in vivo and more specifically within 
the dorsal neural tube during NC development. 
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Discussion 
EMT is essential for embryogenesis, regeneration and cancer metastasis 
and requires interactions with multiple cell types and ECM components 
(Lamouille et al., 2014). Modeling the physiological complexity of EMT is not 
feasible using conventional in vitro cell-based systems. Despite this shortcoming, 
most EMT inhibitors identified to date are discovered through cell-based assays, 
which likely contributes to the lack of effective EMT inhibitors in the clinic (Davis 
et al., 2014). In addition, our knowledge of the essential signaling pathways 
controlling EMT in vivo remains incomplete, due to difficulties in labeling and 
observing EMT in living animals. In this study we take advantage of the unique 
imaging and ex utero development attributes of zebrafish to develop an EMT 
reporter strain, Tg(snai1b:GFP), to directly image EMT in intact animals and 
identify novel in vivo inhibitors of this process. We identified a novel multi-kinase 
inhibitor, called TP-0903, that functions by activating RA signaling, which in turn 
blocks EMT and drives differentiation of NC progenitors toward a non-
ectomesenchymal fates. Remarkably, despite numerous studies examining RA in 
NC development, this is the first study showing RA directly controls EMT in NC 
progenitors during dorsal neural tube development. Finally, as RA is a well-
established differentiation agent, these findings also suggest RA antagonizes 
EMT-dependent pathways controlling de-differentiation and stem-cell-like 
properties, providing an alternative explanation for the effectiveness of retinoids 
as adjuvant therapies to eliminate residual tumor cells in cancer patients. 
Direct comparative analysis of Tg(snai1b:GFP) to previously described NC 
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reporter strains, such as sox10-driven reporters, showed that Tg(snai1b:GFP) 
robustly labels dorsal neural tube progenitors undergoing EMT (Figures 2.1 and 
2.3), allowing us to develop assays for identifying inhibitors of EMT using a 
chemical screening approach. Unexpectedly, we found that inhibition of most 
canonical kinase and actin-remodeling pathways does not overtly affect EMT and 
cell migration in vivo. We suggest that this is due to multiple compensatory 
pathways acting together, both within delaminating cells and the 
microenvironment, to ensure EMT is correctly executed in vivo. This contrasts 
with current 2-D and 3-D in vitro assays of EMT that only partially recapitulate the 
complexities of the microenvironment and thus may be more reliant on single 
pathways to execute an EMT. Having a complementary in vivo model that 
emulates the full spectrum of EMT is crucial for identifying which in vitro EMT 
inhibitors represent the most effective therapeutics in human disease. In addition, 
germ-line transgenic lines allow thousands of Tg(snai1b:GFP) embryos to be 
generated by simple genetic crosses for rapid screening purposes. Future 
studies testing combinations of in vitro EMT inhibitors in Tg(snai1b:GFP) will 
likely uncover essential signaling pathways required for EMT in vivo, and guide 
the use of these inhibitors in human disease and cancer. 
 Early developmental exposure to RA causes overt defects in cranial 
structures in humans and other vertebrates (Lammer et al., 1985; Lee et al., 
1995). Isolated cranial NC cells are highly susceptible to developmental 
reprograming by RA (Williams et al., 2004) but the consequence of this 
reprogramming is not known. Interestingly Cyp26c1, an enzyme that oxidizes 
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and degrades RA to control levels of RA in the neural ectoderm, was established 
as a novel target of neural plate border specifier genes Pax3 and Zic1 (Plouhinec 
et al., 2014). Pax3 and Zic1 directly activate a NC gene regulatory network 
(snail1, snail2, foxd3, and twist1) that is sufficient to promote NC specification 
(Milet et al., 2013; Plouhinec et al., 2014). Together with our data, these findings 
suggest a model in which Pax3 and Zic1 act to suppress RA signaling at the 
neural plate border while simultaneously activating snail1 expression to induce 
EMT.  
Our studies are the first to show RA inhibits cranial NC EMT. There are 
several ways RA could be blocking EMT. For example RA may activate 
transcription of epithelial cell-cell adhesion molecules to prevent detachment 
from the neuroepithelium, as observed in TP-0903 treated embryos (Figure 
2.6C). Consistent with this, increased E-cadherin has been observed in NC cells 
that failed to emigrate from the neural tube in Cyp26a1/c1-/- mutant mice (Uehara 
et al., 2007). Additionally RA treatment increases cytosolic calcium levels (Davis 
et al., 1991) and cell-cell adhesion of cultured NC cells (Smith-Thomas et al., 
1987) and in cancer cell lines RA can activate E-cadherin expression and 
promote cadherin stabilization at cell membranes (Shah et al., 2002; Woo and 
Jang, 2012). These observations together with our data suggest excess RA 
impairs NC EMT and production of migratory NC cells by stimulating Cadherin 
expression and increasing its localization at cell membranes. The 
Tg(snai1b:GFP) line represents a novel tool to isolate and purify dorsal neural 
tube progenitors to determine if RA directly regulates Cadherin expression or if 
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other novel RA-effector pathways inhibit EMT. 
Induction of EMT can generate cancer cells with stem-cell-like 
characteristics and contribute to the formation of a poorly differentiated tumor 
with increased invasion and metastatic potential. Adjuvant therapies that target 
dormant/cancer stem cells are already incorporating RA-like molecules into 
differentiation therapy methods. In the clinic, retinoids are thought to act by 
promoting an arrest in cell proliferation, inducing differentiation and subsequent 
cell death (Nasr et al., 2008; Reynolds, 2000). Pharmacological doses of 
retinoids used in combination with other therapies are being successfully used in 
the treatment of various types of cancers like neuroblastoma, melanoma, and 
leukemia (Tang and Gudas, 2011). Our findings provide an alternative viewpoint 
on retinoid therapy and suggest the positive therapeutic effects of RA observed 
in the clinic may also be due to its role in blocking EMT. Our data designate RA 
as an attractive therapeutic approach to both inhibit EMT and promote 
differentiation of cancer stem cells in vivo. However retinoid resistance restricts 
the clinical benefits of retinoids and continues to be an issue in cancer therapy 
(Freemantle et al., 2003). The standard use of retinoids involves direct 
administration into the blood stream, and its effectiveness depends on the cells’ 
ability to transport and/or metabolize exogenous retinoids. The TP-0903 
compound identified in this study acts through a novel mechanism that increases 
intracellular levels of RA by promoting its biosynthesis, which may alleviate 
retinoid toxicities and resistance. Preclinical studies on established RA-sensitive 
tumor models will allow assessment of TP-0903 as an alternative adjuvant 
	   51	  
therapy to direct RA administration.  
 
Methods 
Generating the Tg(snai1b:GFP) construct and 
 transgenic lines  
The 3042bp proximal snai1b promoter immediately adjacent to the start 
ATG codon was amplified by standard PCR with primers containing BamH1 (5’) 
and EcoR1 (3’) restriction enzyme sites. The amplified fragment was subcloned 
into a modified pEGFP-1 plasmid (Clontech) containing I-SceI meganuclease 
sites flanking the multiple cloning sites and clones verified by restriction digest 
and sequencing. The pSnai1b:GFP:Isce1 plasmid was linearized with I-SceI and 
10pg of the linearized plasmid was injected into wild-type (AB strain) one-cell 
zebrafish embryos and monitored for transient GFP expression in the neural 
tube.  GFP-expressing embryos were grown to produce Tg(snai1b:GFP) 
transgenic germ-line founders. The Tg(snai1b:GFP)zd1100 strain expressed GFP in 
the same locations as endogenous snai1b and used in all subsequent studies 
(see Figures 2.2 and 2.1). 
 
RNA in situ hybridizations 
Embryos were staged by morphological criteria as described (Kimmel et 
al., 1995). Whole-mount in situ hybridizations were carried out as described 
(Thisse et al., 1993) and antisense probes generated for the following probes: 
cyp26a1 (Shelton et al., 2006), krox20 (Oxtoby and Jowett, 1993) and crestin, 
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snai1b, dlx2a, and mitfa (Stewart et al., 2006). The twist1a cDNA was generated 
by one-step RT-PCR and cloned into pGEM-T Easy plasmid (Promega) using 
primers: Forward 5’- GCAATCTGAGCTTTTCCAGAGG- 3’, Reverse 5’- 
ATCCTTATTTTCGCCCTTG- 3’. Antisense twist1a probe was generated using 
T7 polymerase after linearization with Spe1. The hoxb1a probe was generated 
with SP6 polymerase after linearization with EcoRV. Embryos were imaged using 
a Nikon C-DSD115 microscope with an Olympus DP72 camera. Identical settings 
were used to obtain in situ images within data sets. Brightness and contrast for 
final images were adjusted identically across data sets using Photoshop CS4.  
 
Time-lapse confocal imaging  
Zebrafish embryos were mounted in 35 mm glass bottom microwell dishes 
with 1% low-melting point agarose in E3 egg water. Mounted embryos were 
submerged in egg water or egg water containing DMSO, TP-0903, RA and/or 
DEAB. Time-lapse images were acquired using Olympus Fluoview FV1200 
confocal microscope and Olympus FV10-ASW v4.1 software. Olympus 
UPlanSApo 10X/0.45 objective was used to acquire 10x confocal images every 
10-20 minutes and UPlanSApo 60X/1.20W objective was used to acquire 60x 
confocal images every 35 min.  
 
Chemical compounds and small molecule screening 
Tg(snai1b:GFP) zebrafish embryos at ~13 hpf were treated in 12 well 
plates. One mL of egg water containing pharmacological inhibitors or 0.1-1% 
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DMSO as control was used to incubate 8-10 embryos/well. Pharmacological 
inhibitors were removed after 6-12 hrs incubation and embryos screened for EMT 
and migration defects at 20-24 hpf using fluorescent light on an Olympus SZX16 
microscope. TP-0903 (Mollard et al., 2011) was reconstituted to 10 mM in 
DMSO. All-trans-retinoic acid (RA) and Diethylaminobenzaldehyde (DEAB) were 
purchased from Sigma. Stock solutions of RA (10 mM) and DEAB (10 mM) were 
prepared in DMSO. All RA treatments were performed in the dark.   
 
Sectioning  
Zebrafish embryos were sectioned using a vibratome (Leica VT1200 S) as 
described (Westerfield, 1993). Embryos were staged and fixed in 4% 
paraformaldehyde (PFA) at room temperature (RT) for 2 hrs. Fixed embryos 
were rinsed in 1x phosphate-buffer saline (PBS; pH 7.4) 3x 5 min and then 
soaked in .3M sucrose dissolved in 1x PBS overnight (O/N) at 4°C. Yolk sacs 
were removed with forceps before embedding embryos in 17% gelatin dissolved 
in 10% Hanks Saline at 42°C. Gelatin-tissue blocks were cut into 100um thick 
sections using vibratome. Sections were then mounted on slides and imaged, or 
processed and stained as free-floating slices in 12 well plates.    
 
Immunofluorescence 
Embryos were fixed in 4% PFA at RT for 2 hrs and sectioned as described 
above. Slices were rinsed 3x 5 min with .2% Triton-X 100 in PBS and blocked in 
1% DMSO, 2mg/ML BSA, .5% Triton-X 100, and 10% normal goat serum in PBS 
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for 2.5 hrs at RT. Slices were incubated in primary antibody rabbit anti-Cdh1 
(1:400, GeneTex), rabbit anti-Pan Cadherin (1:400, Sigma), and mouse anti-GFP 
(1:400, Clontech Laboratories) O/N at 4°C. Slices were again washed in 1x PBS 
+ .2% Triton-X 100 4x 15 min and blocked for 2.5 hrs at RT. Subsequently slices 
were incubated in secondary antibody donkey anti-mouse 488 (1:400, 
Invitrogen), donkey anti-rabbit 568 (1:400, Invitrogen) O/N at 4°C and washed 4x 
15 min in PBS + .2% Triton-X 100. Processed sections were mounted on slides 
and confocal imaging performed using Olympus Fluoview FV1200 confocal 
microscope with Olympus FV10-ASW v4.1 software. 
   
RNA sequencing 
Embryos were treated at 13 hpf (8 somite) with TP-0903 and DMSO for 1-, 
4- and 8-hrs at 28°C. 35 embryos were collected for each treatment. Four 
biological replicates were prepared for each condition. RNA was harvested using 
Qiagen RNeasy kit (Cat # 74104). Quality of RNA was assessed using 
Bioanalyzer RNA 6000 Nano Chip and RNA-Seq libraries prepared using illumina 
TruSeq Stranded Total RNA Sample Prep Kit with Ribo-Zero (Cat # RS-122-
2401). Sequencing was performed on Illumina HiSeq 2000 using 50 cycle single-
read sequencing v3 kit (Cat # FC-401-3002). Illumina Fatq files were aligned 
using Novoalign to the zebrafish Zv8 genome. All high-throughput sequencing 




	   55	  
References 
 
 Amatangelo, M. D., Goodyear, S., Varma, D. and Stearns, M. E. (2012). 
c-Myc expression and MEK1-induced Erk2 nuclear localization are required for 
TGF-beta induced epithelial-mesenchymal transition and invasion in prostate 
cancer. Carcinogenesis 33, 1965-75. 
 
 Asiedu, M. K., Beauchamp-Perez, F. D., Ingle, J. N., Behrens, M. D., 
Radisky, D. C. and Knutson, K. L. (2014). AXL induces epithelial-to-
mesenchymal transition and regulates the function of breast cancer stem cells. 
Oncogene 33, 1316-24. 
 
 Banjo, T., Grajcarek, J., Yoshino, D., Osada, H., Miyasaka, K. Y., Kida, 
Y. S., Ueki, Y., Nagayama, K., Kawakami, K., Matsumoto, T. et al. (2013). 
Haemodynamically dependent valvulogenesis of zebrafish heart is mediated by 
flow-dependent expression of miR-21. Nat Commun 4, 1978. 
 
 Berndt, J. D., Clay, M. R., Langenberg, T. and Halloran, M. C. (2008). 
Rho-kinase and myosin II affect dynamic neural crest cell behaviors during 
epithelial to mesenchymal transition in vivo. Dev Biol 324, 236-44. 
 
 Billottet, C., Tuefferd, M., Gentien, D., Rapinat, A., Thiery, J. P., Broet, 
P. and Jouanneau, J. (2008). Modulation of several waves of gene expression 
during FGF-1 induced epithelial-mesenchymal transition of carcinoma cells. J 
Cell Biochem 104, 826-39. 
 
 Blackburn, J. S., Liu, S., Wilder, J. L., Dobrinski, K. P., Lobbardi, R., 
Moore, F. E., Martinez, S. A., Chen, E. Y., Lee, C. and Langenau, D. M. 
(2014). Clonal evolution enhances leukemia-propagating cell frequency in T cell 
acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer 
Cell 25, 366-78. 
 
 Buonato, J. M. and Lazzara, M. J. (2014). ERK1/2 blockade prevents 
epithelial-mesenchymal transition in lung cancer cells and promotes their 
sensitivity to EGFR inhibition. Cancer Res 74, 309-19. 
 
 Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., 
Shen, L., Fan, Y., Giri, U., Tumula, P. K. et al. (2013). An epithelial-
mesenchymal transition gene signature predicts resistance to EGFR and PI3K 
inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor 
resistance. Clin Cancer Res 19, 279-90. 
 
 Chou, C. H., Yang, N. K., Liu, T. Y., Tai, S. K., Hsu, D. S., Chen, Y. W., 
Chen, Y. J., Chang, C. C., Tzeng, C. H. and Yang, M. H. (2013). Chromosome 
instability modulated by BMI1-AURKA signaling drives progression in head and 
neck cancer. Cancer Res 73, 953-66. 
	   56	  
 Cichon, M. A., Szentpetery, Z., Caley, M. P., Papadakis, E. S., 
Mackenzie, I. C., Brennan, C. H. and O'Toole, E. A. (2014). The receptor 
tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous 
squamous cell carcinoma. Oncogene 33, 4185-92. 
 
 Clay, M. R. and Halloran, M. C. (2013). Rho activation is apically 
restricted by Arhgap1 in neural crest cells and drives epithelial-to-mesenchymal 
transition. Development 140, 3198-209. 
 
 Colomiere, M., Ward, A. C., Riley, C., Trenerry, M. K., Cameron-Smith, 
D., Findlay, J., Ackland, L. and Ahmed, N. (2009). Cross talk of signals 
between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal 
transition in ovarian carcinomas. Br J Cancer 100, 134-44. 
 
 D'Assoro, A. B., Liu, T., Quatraro, C., Amato, A., Opyrchal, M., 
Leontovich, A., Ikeda, Y., Ohmine, S., Lingle, W., Suman, V. et al. (2014). The 
mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-
mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene 33, 599-
610. 
 
 Dai, W., Bai, Y., Hebda, L., Zhong, X., Liu, J., Kao, J. and Duan, C. 
(2014). Calcium deficiency-induced and TRP channel-regulated IGF1R-PI3K-Akt 
signaling regulates abnormal epithelial cell proliferation. Cell Death Differ 21, 
568-81. 
 
 Davis, F. M., Stewart, T. A., Thompson, E. W. and Monteith, G. R. 
(2014). Targeting EMT in cancer: opportunities for pharmacological intervention. 
Trends Pharmacol Sci 35, 479-88. 
 
 Davis, W. L., Jacoby, B. H., Farmer, G. R. and Cooper, O. J. (1991). 
Changes in cytosolic calcium, bleb formation, and cell death in neural crest cells 
treated with isotretinoin and 4-oxo-isotretinoin. J Craniofac Genet Dev Biol 11, 
105-18. 
 
 Delfini, M. C., De La Celle, M., Gros, J., Serralbo, O., Marics, I., Seux, 
M., Scaal, M. and Marcelle, C. (2009). The timing of emergence of muscle 
progenitors is controlled by an FGF/ERK/SNAIL1 pathway. Dev Biol 333, 229-37. 
 
 Duong, T., Koltowska, K., Pichol-Thievend, C., Le Guen, L., Fontaine, 
F., Smith, K. A., Truong, V., Skoczylas, R., Stacker, S. A., Achen, M. G. et al. 
(2014). VEGFD regulates blood vascular development by modulating SOX18 
activity. Blood 123, 1102-12. 
 
 Ellies, D. L., Langille, R. M., Martin, C. C., Akimenko, M. A. and Ekker, 
M. (1997). Specific craniofacial cartilage dysmorphogenesis coincides with a loss 
of dlx gene expression in retinoic acid-treated zebrafish embryos. Mech Dev 61, 
	   57	  
23-36. 
 
 Erickson, T., French, C. R. and Waskiewicz, A. J. (2010). Meis1 
specifies positional information in the retina and tectum to organize the zebrafish 
visual system. Neural Dev 5, 22. 
 
 Ernst, S., Liu, K., Agarwala, S., Moratscheck, N., Avci, M. E., Dalle 
Nogare, D., Chitnis, A. B., Ronneberger, O. and Lecaudey, V. (2012). 
Shroom3 is required downstream of FGF signalling to mediate proneuromast 
assembly in zebrafish. Development 139, 4571-81. 
 
 Freemantle, S. J., Spinella, M. J. and Dmitrovsky, E. (2003). Retinoids 
in cancer therapy and chemoprevention: promise meets resistance. Oncogene 
22, 7305-15. 
 
 Gjerdrum, C., Tiron, C., Hoiby, T., Stefansson, I., Haugen, H., Sandal, 
T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T. et al. (2010). Axl is an 
essential epithelial-to-mesenchymal transition-induced regulator of breast cancer 
metastasis and patient survival. Proc Natl Acad Sci U S A 107, 1124-9. 
 
 Green, S. A., Simoes-Costa, M. and Bronner, M. E. (2015). Evolution of 
vertebrates as viewed from the crest. Nature 520, 474-82. 
 
 Grille, S. J., Bellacosa, A., Upson, J., Klein-Szanto, A. J., van Roy, F., 
Lee-Kwon, W., Donowitz, M., Tsichlis, P. N. and Larue, L. (2003). The protein 
kinase Akt induces epithelial mesenchymal transition and promotes enhanced 
motility and invasiveness of squamous cell carcinoma lines. Cancer Res 63, 
2172-8. 
 
 Grotegut, S., von Schweinitz, D., Christofori, G. and Lehembre, F. 
(2006). Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-
mediated upregulation of Snail. EMBO J 25, 3534-45. 
 
 Gulhati, P., Bowen, K. A., Liu, J., Stevens, P. D., Rychahou, P. G., 
Chen, M., Lee, E. Y., Weiss, H. L., O'Connor, K. L., Gao, T. et al. (2011). 
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal 
cancer via RhoA and Rac1 signaling pathways. Cancer Res 71, 3246-56. 
 
 Gupta, G. P. and Massague, J. (2006). Cancer metastasis: building a 
framework. Cell 127, 679-95. 
 
 Gupta, P. B., Kuperwasser, C., Brunet, J. P., Ramaswamy, S., Kuo, W. 
L., Gray, J. W., Naber, S. P. and Weinberg, R. A. (2005). The melanocyte 
differentiation program predisposes to metastasis after neoplastic transformation. 
Nat Genet 37, 1047-54. 
 
	   58	  
 Harding, M. J. and Nechiporuk, A. V. (2012). Fgfr-Ras-MAPK signaling 
is required for apical constriction via apical positioning of Rho-associated kinase 
during mechanosensory organ formation. Development 139, 3130-5. 
 
 Hardy, K. M., Yatskievych, T. A., Konieczka, J., Bobbs, A. S. and 
Antin, P. B. (2011). FGF signalling through RAS/MAPK and PI3K pathways 
regulates cell movement and gene expression in the chicken primitive streak 
without affecting E-cadherin expression. BMC Dev Biol 11, 20. 
 
 Hawkins, T. A., Cavodeassi, F., Erdelyi, F., Szabo, G. and Lele, Z. 
(2008). The small molecule Mek1/2 inhibitor U0126 disrupts the 
chordamesoderm to notochord transition in zebrafish. BMC Dev Biol 8, 42. 
 
 Hay, E. D. (1995). An overview of epithelio-mesenchymal transformation. 
Acta Anat (Basel) 154, 8-20. 
 
 Holland, S. J., Pan, A., Franci, C., Hu, Y., Chang, B., Li, W., Duan, M., 
Torneros, A., Yu, J., Heckrodt, T. J. et al. (2010). R428, a selective small 
molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in 
models of metastatic breast cancer. Cancer Res 70, 1544-54. 
 
 Hong, J., Zhou, J., Fu, J., He, T., Qin, J., Wang, L., Liao, L. and Xu, J. 
(2011). Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 
protein and promotes breast cancer cell invasiveness. Cancer Res 71, 3980-90. 
 
 Irie, H. Y., Pearline, R. V., Grueneberg, D., Hsia, M., Ravichandran, P., 
Kothari, N., Natesan, S. and Brugge, J. S. (2005). Distinct roles of Akt1 and 
Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 
171, 1023-34. 
 
 Ishizaki, H., Spitzer, M., Wildenhain, J., Anastasaki, C., Zeng, Z., 
Dolma, S., Shaw, M., Madsen, E., Gitlin, J., Marais, R. et al. (2010). Combined 
zebrafish-yeast chemical-genetic screens reveal gene-copper-nutrition 
interactions that modulate melanocyte pigmentation. Dis Model Mech 3, 639-51. 
 
 Kang, Y. and Massague, J. (2004). Epithelial-mesenchymal transitions: 
twist in development and metastasis. Cell 118, 277-9. 
 
 Kim, E., Youn, H., Kwon, T., Son, B., Kang, J., Yang, H. J., Seong, K. 
M., Kim, W. and Youn, B. (2014). PAK1 tyrosine phosphorylation is required to 
induce epithelial-mesenchymal transition and radioresistance in lung cancer 
cells. Cancer Res 74, 5520-31. 
 
 Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. and 
Schilling, T. F. (1995). Stages of embryonic development of the zebrafish. Dev 
Dyn 203, 253-310. 
	   59	  
 Knecht, A. K. and Bronner-Fraser, M. (2002). Induction of the neural 
crest: a multigene process. Nat Rev Genet 3, 453-61. 
 
 Kong, F. F., Zhu, Y. L., Yuan, H. H., Wang, J. Y., Zhao, M., Gong, X. D., 
Liu, F., Zhang, W. Y., Wang, C. R. and Jiang, B. (2014). FOXM1 regulated by 
ERK pathway mediates TGF-beta1-induced EMT in NSCLC. Oncol Res 22, 29-
37. 
 
 Koorstra, J. B., Karikari, C. A., Feldmann, G., Bisht, S., Rojas, P. L., 
Offerhaus, G. J., Alvarez, H. and Maitra, A. (2009). The Axl receptor tyrosine 
kinase confers an adverse prognostic influence in pancreatic cancer and 
represents a new therapeutic target. Cancer Biol Ther 8, 618-26. 
 
 Kurrey, N. K., Jalgaonkar, S. P., Joglekar, A. V., Ghanate, A. D., 
Chaskar, P. D., Doiphode, R. Y. and Bapat, S. A. (2009). Snail and slug 
mediate radioresistance and chemoresistance by antagonizing p53-mediated 
apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem 
Cells 27, 2059-68. 
 
 Lammer, E. J., Chen, D. T., Hoar, R. M., Agnish, N. D., Benke, P. J., 
Braun, J. T., Curry, C. J., Fernhoff, P. M., Grix, A. W., Jr., Lott, I. T. et al. 
(1985). Retinoic acid embryopathy. N Engl J Med 313, 837-41. 
 
 Lamouille, S., Connolly, E., Smyth, J. W., Akhurst, R. J. and Derynck, 
R. (2012). TGF-beta-induced activation of mTOR complex 2 drives epithelial-
mesenchymal transition and cell invasion. J Cell Sci 125, 1259-73. 
 
 Lamouille, S. and Derynck, R. (2007). Cell size and invasion in TGF-
beta-induced epithelial to mesenchymal transition is regulated by activation of the 
mTOR pathway. J Cell Biol 178, 437-51. 
 
 Lamouille, S., Xu, J. and Derynck, R. (2014). Molecular mechanisms of 
epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15, 178-96. 
 
 Latifi, A., Abubaker, K., Castrechini, N., Ward, A. C., Liongue, C., 
Dobill, F., Kumar, J., Thompson, E. W., Quinn, M. A., Findlay, J. K. et al. 
(2011). Cisplatin treatment of primary and metastatic epithelial ovarian 
carcinomas generates residual cells with mesenchymal stem cell-like profile. J 
Cell Biochem 112, 2850-64. 
 
 Lee, Y. M., Osumi-Yamashita, N., Ninomiya, Y., Moon, C. K., Eriksson, 
U. and Eto, K. (1995). Retinoic acid stage-dependently alters the migration 
pattern and identity of hindbrain neural crest cells. Development 121, 825-37. 
 
 Letamendia, A., Quevedo, C., Ibarbia, I., Virto, J. M., Holgado, O., 
Diez, M., Izpisua Belmonte, J. C. and Callol-Massot, C. (2012). Development 
	   60	  
and validation of an automated high-throughput system for zebrafish in vivo 
screenings. PLoS One 7, e36690. 
 
 Li, Q. Q., Xu, J. D., Wang, W. J., Cao, X. X., Chen, Q., Tang, F., Chen, 
Z. Q., Liu, X. P. and Xu, Z. D. (2009). Twist1-mediated adriamycin-induced 
epithelial-mesenchymal transition relates to multidrug resistance and invasive 
potential in breast cancer cells. Clin Cancer Res 15, 2657-65. 
 
 Lin, J., Wang, X. and Dorsky, R. I. (2011). Progenitor expansion in apc 
mutants is mediated by Jak/Stat signaling. BMC Dev Biol 11, 73. 
 
 Liu, L., Zhu, S., Gong, Z. and Low, B. C. (2008). K-ras/PI3K-Akt 
signaling is essential for zebrafish hematopoiesis and angiogenesis. PLoS One 
3, e2850. 
 
 Liu, R. Y., Zeng, Y., Lei, Z., Wang, L., Yang, H., Liu, Z., Zhao, J. and 
Zhang, H. T. (2014). JAK/STAT3 signaling is required for TGF-beta-induced 
epithelial-mesenchymal transition in lung cancer cells. Int J Oncol 44, 1643-51. 
 
 Lo, H. W., Hsu, S. C., Xia, W., Cao, X., Shih, J. Y., Wei, Y., Abbruzzese, 
J. L., Hortobagyi, G. N. and Hung, M. C. (2007). Epidermal growth factor 
receptor cooperates with signal transducer and activator of transcription 3 to 
induce epithelial-mesenchymal transition in cancer cells via up-regulation of 
TWIST gene expression. Cancer Res 67, 9066-76. 
 
 Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. 
K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A. 
et al. (2012). VEGF inhibits tumor cell invasion and mesenchymal transition 
through a MET/VEGFR2 complex. Cancer Cell 22, 21-35. 
 
 Lu, Z., Ghosh, S., Wang, Z. and Hunter, T. (2003). Downregulation of 
caveolin-1 function by EGF leads to the loss of E-cadherin, increased 
transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer 
Cell 4, 499-515. 
 
 Luesch, H., Chanda, S. K., Raya, R. M., DeJesus, P. D., Orth, A. P., 
Walker, J. R., Izpisua Belmonte, J. C. and Schultz, P. G. (2006). A functional 
genomics approach to the mode of action of apratoxin A. Nat Chem Biol 2, 158-
67. 
 
 Ma, A. C., Fan, A., Ward, A. C., Liongue, C., Lewis, R. S., Cheng, S. H., 
Chan, P. K., Yip, S. F., Liang, R. and Leung, A. Y. (2009). A novel zebrafish 
jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera. 
Exp Hematol 37, 1379-1386 e4. 
 
 Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. 
	   61	  
Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M. et al. (2008). The 
epithelial-mesenchymal transition generates cells with properties of stem cells. 
Cell 133, 704-15. 
 
 Marchetti, A., Colletti, M., Cozzolino, A. M., Steindler, C., Lunadei, M., 
Mancone, C. and Tripodi, M. (2008). ERK5/MAPK is activated by TGFbeta in 
hepatocytes and required for the GSK-3beta-mediated Snail protein stabilization. 
Cell Signal 20, 2113-8. 
 
 Martinez-Morales, P. L., Diez del Corral, R., Olivera-Martinez, I., 
Quiroga, A. C., Das, R. M., Barbas, J. A., Storey, K. G. and Morales, A. V. 
(2011). FGF and retinoic acid activity gradients control the timing of neural crest 
cell emigration in the trunk. J Cell Biol 194, 489-503. 
 
 Matt, N., Ghyselinck, N. B., Wendling, O., Chambon, P. and Mark, M. 
(2003). Retinoic acid-induced developmental defects are mediated by 
RARbeta/RXR heterodimers in the pharyngeal endoderm. Development 130, 
2083-93. 
 
 Milet, C., Maczkowiak, F., Roche, D. D. and Monsoro-Burq, A. H. 
(2013). Pax3 and Zic1 drive induction and differentiation of multipotent, 
migratory, and functional neural crest in Xenopus embryos. Proc Natl Acad Sci U 
S A 110, 5528-33. 
 
 Molina, G. A., Watkins, S. C. and Tsang, M. (2007). Generation of FGF 
reporter transgenic zebrafish and their utility in chemical screens. BMC Dev Biol 
7, 62. 
 
 Mollard, A., Warner, S. L., Call, L. T., Wade, M. L., Bearss, J. J., 
Verma, A., Sharma, S., Vankayalapati, H. and Bearss, D. J. (2011). Design, 
synthesis and biological evaluation of a series of novel Axl kinase inhibitors. ACS 
Med Chem Lett 2, 907-912. 
 
 Nasr, R., Guillemin, M. C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., 
Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, 
B. et al. (2008). Eradication of acute promyelocytic leukemia-initiating cells 
through PML-RARA degradation. Nat Med 14, 1333-42. 
 
 Nguyen, P. T., Tsunematsu, T., Yanagisawa, S., Kudo, Y., Miyauchi, 
M., Kamata, N. and Takata, T. (2013). The FGFR1 inhibitor PD173074 induces 
mesenchymal-epithelial transition through the transcription factor AP-1. Br J 
Cancer 109, 2248-58. 
 
 Nieto, M. A. (2002). The snail superfamily of zinc-finger transcription 
factors. Nat Rev Mol Cell Biol 3, 155-66. 
 
	   62	  
 Niu, N. K., Wang, Z. L., Pan, S. T., Ding, H. Q., Au, G. H., He, Z. X., 
Zhou, Z. W., Xiao, G., Yang, Y. X., Zhang, X. et al. (2015). Pro-apoptotic and 
pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on 
human osteosarcoma U-2 OS and MG-63 cells through the activation of 
mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR 
signaling pathway. Drug Des Devel Ther 9, 1555-84. 
 
 Oxtoby, E. and Jowett, T. (1993). Cloning of the zebrafish krox-20 gene 
(krx-20) and its expression during hindbrain development. Nucleic Acids Res 21, 
1087-95. 
 
 Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H. R., Zhang, Y. 
and Wrana, J. L. (2005). Regulation of the polarity protein Par6 by TGFbeta 
receptors controls epithelial cell plasticity. Science 307, 1603-9. 
 
 Pennisi, D. J. and Mikawa, T. (2009). FGFR-1 is required by epicardium-
derived cells for myocardial invasion and correct coronary vascular lineage 
differentiation. Dev Biol 328, 148-59. 
 
 Plouhinec, J. L., Roche, D. D., Pegoraro, C., Figueiredo, A. L., 
Maczkowiak, F., Brunet, L. J., Milet, C., Vert, J. P., Pollet, N., Harland, R. M. 
et al. (2014). Pax3 and Zic1 trigger the early neural crest gene regulatory 
network by the direct activation of multiple key neural crest specifiers. Dev Biol 
386, 461-72. 
 
 Polyak, K. and Weinberg, R. A. (2009). Transitions between epithelial 
and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev 
Cancer 9, 265-73. 
 
 Pruvot, B., Cure, Y., Djiotsa, J., Voncken, A. and Muller, M. (2014). 
Developmental defects in zebrafish for classification of EGF pathway inhibitors. 
Toxicol Appl Pharmacol 274, 339-49. 
 
 Qian, X., Anzovino, A., Kim, S., Suyama, K., Yao, J., Hulit, J., 
Agiostratidou, G., Chandiramani, N., McDaid, H. M., Nagi, C. et al. (2014). N-
cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal 
transition and stem/progenitor cell-like properties. Oncogene 33, 3411-21. 
 
 Reichl, P., Dengler, M., van Zijl, F., Huber, H., Fuhrlinger, G., Reichel, 
C., Sieghart, W., Peck-Radosavljevic, M., Grubinger, M. and Mikulits, W. 
(2015). Axl activates autocrine transforming growth factor-beta signaling in 
hepatocellular carcinoma. Hepatology 61, 930-41. 
 
 Reynolds, C. P. (2000). Differentiating agents in pediatric malignancies: 
retinoids in neuroblastoma. Curr Oncol Rep 2, 511-8. 
 
	   63	  
 Ronca, R., Di Salle, E., Giacomini, A., Leali, D., Alessi, P., Coltrini, D., 
Ravelli, C., Matarazzo, S., Ribatti, D., Vermi, W. et al. (2013). Long pentraxin-3 
inhibits epithelial-mesenchymal transition in melanoma cells. Mol Cancer Ther 
12, 2760-71. 
 
 Samame Perez-Vargas, J. C., Biondani, P., Maggi, C., Gariboldi, M., 
Gloghini, A., Inno, A., Volpi, C. C., Gualeni, A. V., di Bartolomeo, M., de 
Braud, F. et al. (2013). Role of cMET in the development and progression of 
colorectal cancer. Int J Mol Sci 14, 18056-77. 
 
 Sauka-Spengler, T. and Bronner-Fraser, M. (2008). A gene regulatory 
network orchestrates neural crest formation. Nat Rev Mol Cell Biol 9, 557-68. 
 
 Savagner, P., Yamada, K. M. and Thiery, J. P. (1997). The zinc-finger 
protein slug causes desmosome dissociation, an initial and necessary step for 
growth factor-induced epithelial-mesenchymal transition. J Cell Biol 137, 1403-
19. 
 
 Shah, S., Pishvaian, M. J., Easwaran, V., Brown, P. H. and Byers, S. 
W. (2002). The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated 
carcinoma cell differentiation and proliferation. J Biol Chem 277, 25313-22. 
 
 Shelton, D. N., Sandoval, I. T., Eisinger, A., Chidester, S., Ratnayake, 
A., Ireland, C. M. and Jones, D. A. (2006). Up-regulation of CYP26A1 in 
adenomatous polyposis coli-deficient vertebrates via a WNT-dependent 
mechanism: implications for intestinal cell differentiation and colon tumor 
development. Cancer Res 66, 7571-7. 
 
 Shen, X., Li, J., Hu, P. P., Waddell, D., Zhang, J. and Wang, X. F. 
(2001). The activity of guanine exchange factor NET1 is essential for 
transforming growth factor-beta-mediated stress fiber formation. J Biol Chem 
276, 15362-8. 
 
 Silva, S. R., Bowen, K. A., Rychahou, P. G., Jackson, L. N., Weiss, H. 
L., Lee, E. Y., Townsend, C. M., Jr. and Evers, B. M. (2011). VEGFR-2 
expression in carcinoid cancer cells and its role in tumor growth and metastasis. 
Int J Cancer 128, 1045-56. 
 
 Smith-Thomas, L., Lott, I. and Bronner-Fraser, M. (1987). Effects of 
isotretinoin on the behavior of neural crest cells in vitro. Dev Biol 123, 276-81. 
 
 Stewart, R. A., Arduini, B. L., Berghmans, S., George, R. E., Kanki, J. 
P., Henion, P. D. and Look, A. T. (2006). Zebrafish foxd3 is selectively required 
for neural crest specification, migration and survival. Dev Biol 292, 174-88. 
 
 Sun, X., Meyers, E. N., Lewandoski, M. and Martin, G. R. (1999). 
	   64	  
Targeted disruption of Fgf8 causes failure of cell migration in the gastrulating 
mouse embryo. Genes Dev 13, 1834-46. 
 
 Tang, X. H. and Gudas, L. J. (2011). Retinoids, retinoic acid receptors, 
and cancer. Annu Rev Pathol 6, 345-64. 
 
 Tavares, A. L., Mercado-Pimentel, M. E., Runyan, R. B. and Kitten, G. 
T. (2006). TGF beta-mediated RhoA expression is necessary for epithelial-
mesenchymal transition in the embryonic chick heart. Dev Dyn 235, 1589-98. 
 
 Thiery, J. P., Acloque, H., Huang, R. Y. and Nieto, M. A. (2009). 
Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-
90. 
 
 Thisse, C., Thisse, B., Schilling, T. F. and Postlethwait, J. H. (1993). 
Structure of the zebrafish snail1 gene and its expression in wild-type, spadetail 
and no tail mutant embryos. Development 119, 1203-15. 
 
 Tolero Pharmaceuticals. (2015). TP-0903, vol. 2015: [Internet] http://www.toleropharmaceuticals.com/TP-­‐0903.html. 
 
 Uehara, M., Yashiro, K., Mamiya, S., Nishino, J., Chambon, P., Dolle, 
P. and Sakai, Y. (2007). CYP26A1 and CYP26C1 cooperatively regulate 
anterior-posterior patterning of the developing brain and the production of 
migratory cranial neural crest cells in the mouse. Dev Biol 302, 399-411. 
 
 Valles, A. M., Boyer, B., Badet, J., Tucker, G. C., Barritault, D. and 
Thiery, J. P. (1990). Acidic fibroblast growth factor is a modulator of epithelial 
plasticity in a rat bladder carcinoma cell line. Proc Natl Acad Sci U S A 87, 1124-
8. 
 
 Valles, A. M., Boyer, B., Tarone, G. and Thiery, J. P. (1996). Alpha 2 
beta 1 integrin is required for the collagen and FGF-1 induced cell dispersion in a 
rat bladder carcinoma cell line. Cell Adhes Commun 4, 187-99. 
 
 Vardouli, L., Moustakas, A. and Stournaras, C. (2005). LIM-kinase 2 
and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by 
transforming growth factor-beta. J Biol Chem 280, 11448-57. 
 
 Verma, N., Keinan, O., Selitrennik, M., Karn, T., Filipits, M. and Lev, S. 
(2015). PYK2 sustains endosomal-derived receptor signalling and enhances 
epithelial-to-mesenchymal transition. Nat Commun 6, 6064. 
 
 Vuoriluoto, K., Haugen, H., Kiviluoto, S., Mpindi, J. P., Nevo, J., 
Gjerdrum, C., Tiron, C., Lorens, J. B. and Ivaska, J. (2011). Vimentin 
regulates EMT induction by Slug and oncogenic H-Ras and migration by 
	   65	  
governing Axl expression in breast cancer. Oncogene 30, 1436-48. 
 
 Wan, X. B., Long, Z. J., Yan, M., Xu, J., Xia, L. P., Liu, L., Zhao, Y., 
Huang, X. F., Wang, X. R., Zhu, X. F. et al. (2008). Inhibition of Aurora-A 
suppresses epithelial-mesenchymal transition and invasion by downregulating 
MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 29, 1930-7. 
 
 Weiser, D. C., Pyati, U. J. and Kimelman, D. (2007). Gravin regulates 
mesodermal cell behavior changes required for axis elongation during zebrafish 
gastrulation. Genes Dev 21, 1559-71. 
 
 Westerfield, M. (1993). The zebrafish book : a guide for the laboratory 
use of zebrafish (Brachydanio rerio). Eugene, OR: M. Westerfield. 
 
 Williams, S. S., Mear, J. P., Liang, H. C., Potter, S. S., Aronow, B. J. 
and Colbert, M. C. (2004). Large-scale reprogramming of cranial neural crest 
gene expression by retinoic acid exposure. Physiol Genomics 19, 184-97. 
 
 Woo, Y. J. and Jang, K. L. (2012). All-trans retinoic acid activates E-
cadherin expression via promoter hypomethylation in the human colon carcinoma 
HCT116 cells. Biochem Biophys Res Commun 425, 944-9. 
 
 Xie, L., Law, B. K., Chytil, A. M., Brown, K. A., Aakre, M. E. and 
Moses, H. L. (2004). Activation of the Erk pathway is required for TGF-beta1-
induced EMT in vitro. Neoplasia 6, 603-10. 
 
 Yadav, A., Kumar, B., Datta, J., Teknos, T. N. and Kumar, P. (2011). IL-
6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal 
transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 9, 1658-
67. 
 
 Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., 
Come, C., Savagner, P., Gitelman, I., Richardson, A. and Weinberg, R. A. 
(2004). Twist, a master regulator of morphogenesis, plays an essential role in 
tumor metastasis. Cell 117, 927-39. 
 
 Yu, L., Hebert, M. C. and Zhang, Y. E. (2002). TGF-beta receptor-
activated p38 MAP kinase mediates Smad-independent TGF-beta responses. 
EMBO J 21, 3749-59. 
 
 Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., 
Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K. et al. (2012). Activation 
of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. 
Nat Genet 44, 852-60. 
 
 Zheng, H. X., Cai, Y. D., Wang, Y. D., Cui, X. B., Xie, T. T., Li, W. J., 
	   66	  
Peng, L., Zhang, Y., Wang, Z. Q., Wang, J. et al. (2013). Fas signaling 
promotes motility and metastasis through epithelial-mesenchymal transition in 


















































Figure 2.1.  Generating an NC EMT reporter during development. (A) Dorsal 
views of whole mount in situ hybridization of snail1b mRNA expression (left) 
compared to maximal z-projections of double transgenic Tg(snai1b:GFP); 
Tg(sox10:RFP) zebrafish embryos (right) at indicated developmental time points. 
Tg(snai1b:GFP) expresses GFP in the neuroepithelium (white arrow head) and 
neural plate border cells (white arrow), similar to endogenous snail1b mRNA 
expression (black arrow and arrowhead). Comparison of Tg(snai1b:GFP) with 
Tg(sox10:RFP) shows GFP is expressed in both the neuroepithelium and lateral 
plate border, whereas RFP labels delaminating NC cells at the neural plate 
border, and partially overlaps with GFP (yellow cells). In migrating NC cells, GFP 
and RFP are co-expressed in the first two cranial streams (numbered). (B) 
Lateral views of brightfield (top) or epifluorescent images (bottom) of 24 hpf 
embryos comparing snail1b mRNA in situ hybridization expression in the trunk 
NC and Tg(snai1b:GFP);Tg(sox10:RFP) embryos showing Tg(snai1b:GFP) 
labels the same region as endogenous snail1b mRNA and co-labels with 
sox10:RFP in trunk NC cells (white arrows).  







Figure 2.2.  Developmental expression of Tg(snai1b:GFP). (A) Tg(snai1b:GFP) 
labels cells during gastrulation at 6.5 hpf in involuting mesendoderm cells 
(arrow), (B) and within the anterior portion of the neuroepithelium (arrow) at 10 
hpf. (C) When cranial NC EMT is beginning to initiate at 14 hpf GFP positive cells 
are found in the neuroepithelium and along the neural plate border (arrow). (D) 
By 18 hpf GFP expression can be seen in the notochord and within cranial neural 
crest streams (arrows). (E) At 24 hpf Tg(snai1b:GFP) labels trunk NC cells 
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Figure 2.3.  Tg(snai1b:GFP) labels dorsal neural tube progenitors that display 
morphological cell behaviors of EMT. (A) Transverse hindbrain sections in double 
transgenic Tg(snai1b:GFP); Tg(sox10:RFP) embryos at 15 and 18 hpf (single 
confocal z plane, 40x) showing snai1b-driven GFP is expressed in dorsal neural 
tube progenitor cells at 15 hpf, while both GFP and sox10-driven RFP are 
expressed in cells adjacent to the neural tube and migration NC cells. (B) 
Transverse hindbrain sections of Tg(snai1b:GFP) embryos at 17 hpf processed 
for immunofluorescence analysis of a-Cdh1 (ECAD) and GFP. Bottom row 
displays higher magnification views of boxed regions, and shows decreased 
ECAD levels in GFP-positive cells compared to ventral neural tube. (C) 
Schematic illustrating imaging area (top) and cell delamination behavior (bottom 
left) derived from confocal time-lapse images of Tg(snai1b:GFP); Tg(sox10:RFP) 
embryos (bottom right), which captured 2 cells delaminating out of the 


















Figure 2.4.  Dorsal midline neural epithelial progenitor cells display novel 
delamination behaviors of EMT. Schematic illustrating imaging area (top) and 
novel delamination behavior of a dorsal midline neuroepithelial progenitor (left), 
which is derived from confocal time-lapse images of Tg(snai1b:GFP); 
Tg(sox10:RFP) embryos (right). Images show a GFP-positive cell initially 
spanning the dorsal midline before contracting apical attachments from each side 
of neuroepithelium. Subsequently, GFP-positive cells detach and become 
rounded with filopodia and blebbing protrusions, and ultimately express sox10-
mRFP at cell membranes. See also Movie S3. 
 
 










Figure 2.5.  Small molecule screening assay to identify inhibitors of EMT and cell 
migration using Tg(snai1b:GFP) zebrafish embryos. Tg(snai1b:GFP) embryos 
were treated after NC induction at ~11 hpf in 12 well plates (see Methods). 
Embryos were incubated at 28°C with pharmacological inhibitors or DMSO for 
12-13 hrs and visualized at 24 hpf after majority of cranial NC EMT has been 
completed and migration initiated. Pharmacological inhibitors that affect EMT and 
cell migration display an accumulation of GFP-positive cells within the neural 








































Figure 2.6.  Chemical screening with Tg(snai1b:GFP) identifies TP-0903 as an 
inhibitor of NC EMT. (A) Dorsal views of Tg(snai1b:GFP) embryos treated with 
DMSO (top) or TP-0903 (bottom) at 11.5 hpf and imaged at indicated time points 
by 10x confocal time-lapse microscopy. TP-0903 treated embryos accumulate 
GFP-positive cells in the dorsal neural tube (arrowhead) and lateral cells remain 
associated with the neural plate border and are fused (compare numbered 
streams in DMSO control to numbered asterisks in TP-0903). (B) Transverse 
sections of DMSO (top) and TP-0903 treated (bottom) Tg(snai1b:GFP); 
Tg(sox10:RFP) embryos at 24 hpf, showing TP-0903 causes accumulation of 
GFP-positive cells in the dorsal neural tube. (C) Transverse sections through 
hindbrain of Tg(snai1b:GFP) embryos at 24 hpf treated with DMSO (top) and TP-
0903 (bottom) and analyzed by immunofluorescence for a-pan-Cadherin and 
GFP, showing GFP-positive cells in TP-0903 treated embryos maintain Cadherin 
levels and cell-cell adhesion within the neural tube. (D) Dorsal views of DMSO 
(left) and TP-0903 treated (right) embryos at 18 hpf processed for twist1a mRNA 
in situ hybridization showing TP-0903 significantly reduces twist1a expression 



































   




   
   
  
         Tg(snail1b:eGFP)         
E E
15 hpf 17 hpf
E E



















Figure 2.7.  TP-0903 acts by inducing retinoic acid signaling in zebrafish 
embryos. (A) Heat map schematic showing the 50 most differentially expressed 
transcripts from RNA-Seq as measured by log2 ratio from 4 hr treated DMSO 
and TP-0903 embryos. (B) Ingenuity pathway analysis of differentially expressed 
genes in TP-0903 treated embryos reveals RA signaling pathways are 
exclusively activated. Bars represent the p-value for each RA pathway 
(expressed as -1 X log of the p-value). The yellow line represents the ratio of the 
number of genes from our data set represented within each pathway to the total 
number of genes in each pathway. (C) Lateral (left panels) and dorsal flat-
mounted views (right panels) of in situ hybridization at 16 hpf for two genes, 
cyp26a1 and hoxb1a, identified as elevated by RNA-Seq after 4 hr TP-0903 
treatment. In all panels krox20 (red) is used as a marker of rhombomeres r3 and 
r5 (red stain). (D) Lateral (left panels) and dorsal flat-mounted views (right 
panels) of embryos treated at 13 hpf with RA mimic TP-0903 expression effects 
















Figure 2.8.  TP-0903 blocks ectomesenchyme differentiation and promotes 
melanophore differentiation. Dorsal views of embryos treated with DMSO or TP-
0903 at 3-somite stage and fixed at the indicated time points for processing by 
whole mount in situ hybridization and bright field microscopy with indicated 
probes or direct visualization of pigment cells. (A) Compared to controls (top 
panel), TP-0903 completely inhibits dlx2a expression in cranial NC streams (n= 
24). (B) Analysis of TP-0903 treated embryos with the pan-NC marker crestin 
shows NC cells are induced but fail to migrate away, and the first two cranial NC 
streams are fused together, as indicated by numbered asterisks. (C) Stalled NC 
cells in TP-0903 treated embryos express the melanophore precursor marker 
mitfa (black arrows). (D) Conversion of ectomesenchymal cells to non-
ectomesenchymal cells causes the accumulation of melanophores on the dorsal 
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Figure 2.9.  Retinoic acid controls cranial NC EMT, cell migration, and 
ectomesenchyme differentiation. (A) Dorsal views of maximal z-projection 
confocal images of Tg(snai1b:GFP); Tg(sox10:RFP) embryos treated with 
indicated compounds at 11.5 hpf. TP-0903 inhibits NC EMT and cell migration, 
which is rescued by co-treatment with DEAB, an inhibitor of retinaldehyde 
dehydrogenase required for retinoic acid biosynthesis. In contrast, direct 
treatment with RA bypasses the requirement for retinaldehyde dehydrogenase 
and is not rescued by DEAB. (B) Transverse sections through the hindbrain of 
Tg(snail1b); Tg(sox10:RFP) embryos at 24 hpf treated with DMSO, TP-0903 and 
RA confirms RA treatment causes accumulation of GFP-positive dorsal neural 
tube cells similar to TP-0903 treatment. (C) Dorsal views of 24 hpf embryos 
processed by whole mount in situ hybridization for twist1a and dlx2a mRNA 
showing inhibition of RA synthesis in TP-0903 treated embryos rescues 
expression of these genes in NC streams (numbered), while RA treatment itself 
mimics TP-0903 and blocks expression of twist1a and dlx2a. (D) Dorsal views of 
48 hpf embryos showing melanophores accumulate on the head of TP-0903 
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Table 2.1.  Small molecules screened in Tg(snai1b:GFP) embryos to identify in 
vivo regulators of EMT and cell migration. Initial concentrations of 10 uM, 20 uM, 









































































JAK2 (Kim et al., 2014) N/A (Yadav et al., 2011) (Ma et al., 2009) 
AG490 EGFR  
JAK2 
(Colomiere et al., 2009; 
Liu et al., 2014; Lo et 
al., 2007; Verma et al., 
2015) 
N/A (Lu et al., 2003; Yadav 
et al., 2011) 
(Lin et al., 2011; Ma 
et al., 2009; Pruvot et 
al., 2014) 
U0126 MEK1/2 (Buonato and Lazzara, 
2014; Kong et al., 
2014; Latifi et al., 2011; 
Wan et al., 2008; Xie et 
al., 2004; Zheng et al., 
2013) 
N/A (Amatangelo et al., 
2012; Grotegut et al., 
2006; Hong et al., 
2011; Marchetti et al., 
2008; Yu et al., 2002) 
(Banjo et al., 2013; 
Duong et al., 2014; 
Hawkins et al., 2008; 
Ishizaki et al., 2010; 





N/A (Lu et al., 2012; 
Samame Perez-Vargas 
et al., 2013; Silva et al., 
2011) 
N/A 





(Ozdamar et al., 2005; 
Shen et al., 2001; 
Tavares et al., 2006; 
Vardouli et al., 2005) 
(Berndt et al., 2008; 
Clay and Halloran, 
2013; Ernst et al., 
2012; Harding and 
Nechiporuk, 2012; 
Weiser et al., 2007) 
PD173074 FGFR 
 
(Nguyen et al., 2013; 
Qian et al., 2014) 
N/A (Billottet et al., 2008; 
Savagner et al., 1997; 
Sun et al., 1999; Valles 
et al., 1990; Valles et 
al., 1996) 
(Erickson et al., 2010; 
Letamendia et al., 
2012; Luesch et al., 
2006; Martinez-
Morales et al., 2011) 
SU5402 FGFR 
 
(Pennisi and Mikawa, 
2009; Ronca et al., 
2013) 
(Delfini et al., 
2009; Hardy 
et al., 2011) 
“ “ (Erickson et al., 2010; 
Harding and 
Nechiporuk, 2012; 
Luesch et al., 2006; 
Molina et al., 2007) 
MK2206 AKT1/2/3 N/A N/A (Grille et al., 2003; 
Gulhati et al., 2011; Irie 
et al., 2005; Lamouille 
et al., 2012; Lamouille 
and Derynck, 2007) 
(Blackburn et al., 
2014; Dai et al., 2014) 
VX680 AURK 
A/B/C 
(Wan et al., 2008) N/A (Chou et al., 2013; 
D'Assoro et al., 2014) 
N/A 
MLN8237 AURKA (D'Assoro et al., 2014; 
Niu et al., 2015) 
N/A “ “ N/A 
SGI7079 AXL (Byers et al., 2013) N/A (Cichon et al., 2014; 
Gjerdrum et al., 2010; 
Koorstra et al., 2009; 
Reichl et al., 2015; 
Vuoriluoto et al., 2011; 
Zhang et al., 2012) 
N/A 
MP470 AXL (Asiedu et al., 2014) N/A “ “ N/A 
R428 AXL (Holland et al., 2010) N/A “ “ N/A 
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Abstract 
Malignant melanoma is a highly aggressive and treatment resistant 
cancer. Recent advances in targeted therapies and immunotherapies developed 
to treat advanced melanoma are promising but fail to show significant efficacy 
and indicate a need to identify other therapeutic options. AXL is a receptor 
tyrosine kinase (RTK) that has emerged as a potential therapeutic target for 
melanoma. AXL is overexpressed and highly active in aggressive and 
undifferentiated human melanomas and its expression in melanoma cell lines 
regulates invasive and migratory behavior in vitro. Expression of AXL is 
upregulated in melanoma cells that acquire resistance to BRAF inhibitors, 
suggesting dual targeting of AXL and BRAF could lead to more durable 
responses in BRAF-mutant melanoma patients. Here we establish a preclinical 
model of AXL-dependent melanoma invasion and show for the first time in vivo 
that AXL cooperates with BRAF to transform primary melanocytes and 
accelerate melanoma formation, growth, and invasion. This preclinical model will 
aid in the identification of AXL-dependent mechanisms driving malignant 
melanoma and the evaluation and identification of effective AXL inhibitors for the 
treatment of melanoma.   
   
Introduction 
Metastatic melanoma is a notoriously aggressive and treatment-resistant 
disease. Therefore there is an urgent need to discover new therapies (Niezgoda 
et al., 2015). Recent breakthroughs have provided novel immunotherapies 
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targeted at PD-1 (nivolumab and pembrolizumaband) and CTLA-4 (ipilimumab) 
for the treatment of advanced melanoma (Dummer et al., 2015). Additionally, 
rational approaches, based on identifying novel melanoma target genes have 
shown great promise. For example, BRAF-mutant melanomas show a dramatic 
response in tumor regression when treated with BRAF and MEK inhibitors such 
as dabrafenib and trametinib, respectively (Flaherty et al., 2012a; Flaherty et al., 
2012b; Mandal et al., 2015). Unfortunately, only small subsets of patients 
respond to immunotherapies and a majority of mutant BRAF tumors acquire 
resistance, resulting in more aggressive tumors that quickly overcome the patient 
(Strickland et al., 2015). In contrast to BRAF-mutant melanomas, NRAS-mutant 
tumors have very limited treatment options and poor overall survival (Ji et al., 
2012; Johnson and Puzanov, 2015). Thus, new therapeutic options, validated in 
preclinical animal models, are needed to improve the outcomes of all melanoma 
patients.  
The oncogenic signaling pathways that drive melanoma cooperate with 
genetic embryonic signals during tumor initiation and progression. The 
transcriptional program that drives epithelial-to-mesenchymal transition (EMT) 
during melanocyte development and specification has been shown to predispose 
melanocytes to high metastatic propensity (Gupta et al., 2005). EMT stimulates 
epithelial cells to dissociate from neighboring cells, which facilitates metastatic 
spread (Thiery et al., 2009; Yang and Weinberg, 2008). Expression of genes that 
induce EMT transforms melanocytes into malignant melanomas and correlates 
with poor patient prognosis (Alonso et al., 2007; Gupta et al., 2005; Hoek et al., 
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2004). Cancer cells undergoing EMT acquire stem cell properties (Mani et al., 
2008), enhanced survival (Barrallo-Gimeno and Nieto, 2005; Lu et al., 2014), 
escape from immune surveillance (Knutson et al., 2006; Kudo-Saito et al., 2009), 
and are resistance to standard chemotherapies and tyrosine kinase inhibitors 
(TKI) (Chung et al., 2011; Rho et al., 2009; Sequist et al., 2011). Despite 
numerous studies demonstrating EMT programs can contribute to many stages 
of cancer progression, the role of EMT in cancer metastasis is still highly debated 
(Tarin et al., 2005; Thompson et al., 2005). This is in part due to the fact that the 
EMT program has not been clearly defined during cancer progression, which 
makes it difficult to study in the clinic. Elucidating the pathways controlling EMT 
in physiologically relevant preclinical cancer models will be critical to understand 
the role of EMT during tumor metastasis. Additionally these studies will aid in 
understanding the metastatic process of cancers like melanoma and identifying 
therapies against the mesenchymal phenotype. 
Expression of AXL receptor tyrosine kinase is strongly associated with the 
mesenchymal phenotype and has emerged as a potential therapeutic target. 
Overexpression of AXL correlates with poor patient survival in several cancers, 
facilitates EMT, promotes cancer stem cells, and underlies resistance to 
chemotherapies and TKIs (Byers et al., 2013; Dufies et al., 2011; Gjerdrum et al., 
2010; Koorstra et al., 2009; Liu et al., 2009; Wilson et al., 2014; Zhang et al., 
2012). AXL is highly active and overexpressed in malignant melanomas and its 
expression in melanoma cell lines regulates invasive and migratory behavior in 
vitro (Sensi et al., 2011; Tworkoski et al., 2011). Melanoma cells with elevated 
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expression of AXL acquire resistance to the PLX4720 BRAF inhibitor, suggesting 
that combination targeting of both BRAF and AXL may prevent BRAF resistance 
in patients (Johannessen et al., 2010; Villanueva et al., 2010).   
Here we explore the physiological function of AXL in promoting melanoma 
formation and malignant progression. We established an in vivo zebrafish 
melanoma model that overexpresses AXL and tested the ability of AXL to 
promote melanocyte transformation and accelerate tumor initiation, growth, and 
invasion. We found that AXL cooperates with mutant BRAF to accelerate 
melanocyte transformation, tumor onset, growth, and invasion. Additionally we 
tested the ability of AXL to activate EMT programs in vivo by characterizing the 
signaling pathways in AXL-driven melanomas using RNA-Seq. We found AXL-
overexpressing tumors negatively correlated with an EMT gene signature in vivo 
despite numerous studies demonstrating AXL can promote EMT in cancer cell 
lines. Additionally, we generated an AXL mutant to determine if endogenous axl 
is required to promote melanoma in our zebrafish melanoma model. These 
studies validate AXL as a potential therapeutic target for melanoma treatment 
and provide a preclinical model to explore AXL-dependent mechanisms driving 






	   82	  
Results 
AXL cooperates with BRAF to promote and accelerate 
melanoma formation 
To determine if AXL expression is sufficient to promote and accelerate 
melanoma in vivo, we generated melanoma models using transgenic zebrafish 
that specifically express human AXL alone or in combination with the common 
melanoma-associated BRAFV600E mutation. For our studies we used an 
established zebrafish melanoma model expressing BRAFV600E in p53-mutant 
melanocytes also lacking mitfa and pigment (Ceol et al., 2011). 
Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- fish have no melanocytes due to mutation 
in the transcription factor mitfa, thus without melanocytes these fish do not 
develop melanoma.  However, when embryos from these fish are injected with a 
rescuing DNA plasmid containing the wild-type mitfa gene (called miniCoopR), it 
rescues melanocytes in a mosaic fashion and fish develop melanomas within 8-
10 weeks (Ceol et al., 2011). We have engineered the miniCoopR rescue 
plasmid to co-express AXL and mitfa in the rescued melanocytes (Figure 3.1A). 
We cloned human AXL into the miniCoopR plasmid with a green fluorescent 
protein (GFP) tag and injected the rescue plasmid into 
Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- and p53-/-;mitfa-/- embryos. Injected 
embryos were screened weekly for primary tumor onset followed by florescence 
microscopy to validate that tumors express GFP, indicative of tumors that have 
arisen from AXL-expressing cells (Figure 3.1A). Tumor onset was compared in 
parallel to embryos injected with a control rescue plasmid miniCoopR-GFP and a 
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positive control rescue plasmid containing SETDB1, a previously described gene 
known to accelerate melanoma onset (Ceol et al., 2011).  
    Tumor incidence curves for p53-/-;mitfa-/- fish injected with miniCoopR-
AXL-GFP rescue plasmid showed that AXL alone does not drive melanoma 
formation (Figure 3.1B). However, Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- injected 
with miniCoopR-AXL-GFP or miniCoopR-AXL-polyA plasmid resulted in the 
formation of melanoma at a significantly accelerated rate compared to 
Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/-  fish injected with control miniCoopR-GFP 
rescue plasmid (p value < .0001, Figure 3.1B). Additionally, AXL accelerates 
onset of melanoma similar to SETDB1, a previously reported accelerator of 
melanoma. These results indicate that expression of AXL alone is not sufficient 
to drive melanoma formation; however this is the first report demonstrating that 
AXL cooperates with BRAF to promote and accelerate melanoma formation.  
 
AXL drives melanoma formation more effectively than 
developmental EMT programs  
We compared the ability of AXL to promote tumor onset to regulators of 
EMT that promote malignant transformation and drive metastasis. A zebrafish 
melanoma model was generated overexpressing a member of the Snail family, 
snai1b, one the most widely studied families of EMT effectors. Expression of 
Snail family members are elevated in transformed melanocytes and enhance 
developmental EMT programs that promote tumor progression, invasion, and 
metastasis (Gupta et al., 2005; Peinado et al., 2007). As expected, we observed 
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snai1b overexpression significantly accelerated tumor formation compared to 
control tumors (Figure 3.1B). Surprisingly, AXL accelerated melanoma formation 
at a higher rate compared to snai1b-expressing melanomas. These observations 
indicate that AXL can promote transformation of melanocytes more effectively 
than drivers of developmental EMT programs, which have been shown to 
promote melanoma formation.   
 
AXL transforms primary melanocytes and accelerates 
nevi formation  
 EMT can give rise to cancer stem cells and promote tumor initiation (Mani 
et al., 2008). In melanoma, expression of EMT effectors such as snai1b in nevi 
can malignantly transform cells and promote melanoma formation, invasion and 
metastasis (Alonso et al., 2007; Gupta et al., 2005; Hoek et al., 2004). Recent 
studies report that AXL is sufficient to directly induce EMT and activate the 
cancer stem cell phenotype (Asiedu et al., 2014), but the role of AXL in driving 
melanocyte transformation has not been explored. AXL is expressed at low 
levels in primary melanocytes, but is elevated in melanomas (Quong et al., 1994; 
Sensi et al., 2011). These observations, together with our findings that AXL 
overexpression can accelerate tumor onset, suggest that overexpression of AXL 
may promote melanocyte transformation. 
 To distinguish the ability of AXL to reprogram primary melanocytes and 
drive malignant transformation, we examined the rate of fish nevi formation in 
AXL-overexpressing melanocytes within our transgenic zebrafish melanoma 
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model. Additionally, we monitored nevi-expressing, fluorescently-tagged AXL 
every 2 weeks to visualize development of GFP-expressing tumor masses 
arising from malignantly transformed AXL-expressing cells. In our screen, fish 
nevi were identified as hyperpigmented patches of ectopic melanocytes at least 2 
mm wide. We found that overexpression of AXL in primary melanocytes 
accelerated nevi formation compared to rescued melanocytes from control fish 
without AXL expression (Figure 3.2A). Moreover, AXL expression transformed 
nevi into tumor masses (Figure 3.2B). Theses studies highlight the ability of AXL 
to reprogram primary melanocytes and accelerate the transformation of nevi into 
malignant melanoma.  
 
AXL accelerates tumor growth and invasion in vivo 
 Previous studies demonstrated that AXL can accelerate growth and 
invasion of cancer cell lines in vitro and promote tumor growth in mouse 
xenograft models (Li et al., 2009; Shieh et al., 2005; Ye et al., 2010). To 
determine if AXL can increase tumor growth and invasion of melanoma in vivo 
we evaluated the growth of our AXL overexpressing melanomas compared to 
control melanomas without AXL overexpression. Tumor size was measured with 
calipers once a week after tumors became visually apparent. Analysis of the 
tumor growth curve indicated overexpression of AXL accelerated melanoma 
growth in vivo compared to control tumors (Figure 3.3A). Additionally melanomas 
with AXL overexpression were more aggressive than control tumors generated in 
the same Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- genetic background. Histological 
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sections of tumors revealed AXL-expressing melanomas become more invasive 
at early stages of tumor development. Melanomas from control tumors assessed 
at a later stage of tumor progression, 5 mm3, grow outward on the skin and do 
not break though the basement membrane (Figure 3.3B). This is in contrast to 
AXL-driven melanomas that begin to locally invade and break through the 
basement membrane by 1 mm3 (Figure 3.3B). As the AXL-driven melanomas 
continue to develop and reach 3 mm3 in size, they completely invade the 
underlying muscle. These studies show for the first time that AXL can enhance 
melanoma growth and invasion in vivo.           
 
AXL-dependent signaling pathways driving melanoma  
onset and invasion 
To determine which AXL-dependent signaling pathways regulate 
melanoma onset and invasion, we performed RNA-Seq analysis on AXL-
overexpressing and control tumors. We collected tumors within the same size 
range of approximately 2 mm3, an earlier stage of tumor development, when 
differences in transcriptional invasion programs can be clearly assessed by RNA-
Seq analysis. RNA was extracted from AXL-overexpressing tumors and control 
tumors to analyze relative levels of gene expression. We hypothesized AXL 
expression would activate EMT programs to drive melanoma invasion. 
Surprisingly, through a gene-set-enrichment analysis (GSEA) we identified the 
EMT pathway was significantly downregulated in AXL-overexpressing tumors 
(Figure 3.4A). These results indicate that AXL may function through an 
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alternative method in vivo. Interestingly, we found a significant enrichment for 
factors involved in the blood coagulation system, which could represents a novel 
AXL-dependent mechanism driving transformation and invasion of cancer cells.  
 
Future direction: is AXL required to promote melanoma  
onset, growth, and invasion? 
 To directly test whether AXL is required for accelerated tumor onset, 
growth, and invasion we aimed to generate a zebrafish melanoma model lacking 
endogenous zebrafish axl expression. To test this, we generated a zebrafish axl 
mutant to cross into the Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- transgenic 
zebrafish melanoma model. To generate an axl mutant we used the 
CRISPR/Cas9 system, a new genome editing technology validated in zebrafish 
(Chang et al., 2013; Hruscha et al., 2013; Jao et al., 2013). With help from the 
University of Utah mutagenesis core we generated a guide RNA (gRNA) 
designed to target exon 4 of the axl locus and several null alleles of axl were 
generated. The axlΔ4, axlΔ7, axlΔ11 alleles all harbor frame-shift deletions in exon 
4 that generate premature stop codons upstream of the transmembrane domain 
and the kinase domain that is required for AXL signaling (Braunger et al., 1997; 
Fridell et al., 1996). 
 To generate zebrafish melanomas lacking endogenous axl expression, the 
axl mutant will be generated in the p53-/-;mitfa-/- genetic background and crossed 
to the Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/-  melanoma model. MiniCoopR-MITF-
RFP rescue plasmids will be injected into 1-cell stage 
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Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- and Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/-
;axl-/-  zebrafish embryos and tumor onset, growth, and invasion will be compared 
in the two genetic backgrounds (Figure 3.5A). AXL has previously been 
implicated in regulating tumor stroma through modulation of tumor-associated 
vasculature and immune cell function (Ye et al., 2010). To test whether axl is 
necessary in the tumor microenvironment to promote melanoma invasion, 
miniCoopR-AXL-GFP will be injected into the Tg(mitfa:BRAF(V600E));p53-/-
;mitfa-/- and Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/-;axl-/- genetic backgrounds and 
tumor onset growth and invasion will be compared (Figure 3.5B). Together these 
studies will determine the necessity of axl in regulating multiple roles of 
tumorgenesis.   
 
Discussion 
In this study, we investigated the various roles of AXL in melanoma, 
including its role in promoting melanocyte transformation, tumor initiation/onset, 
growth, and invasion. We generated an in vivo zebrafish model of AXL-driven 
melanoma and demonstrated that AXL cooperates with the BRAFV600E mutation 
to accelerate melanoma onset. Additionally, we found that cooperation of AXL 
with BRAFV600E mutation accelerated melanocyte transformation into nevi and 
promoted tumor growth and invasion in vivo. Finally, our RNA sequencing 
analysis of AXL-overexpressing tumors revealed AXL does not activate EMT 
programs in vivo as previously suggested from in vitro studies and indicates 
other AXL dependent pathways may be regulating invasion in our zebrafish 
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melanoma model. These studies provide the first evidence that AXL can 
cooperate with BRAF mutations to promote melanoma in vivo and support the 
development of targeted therapy against AXL for the treatment of BRAF-driven 
melanomas.  
Melanoma is the most aggressive form of skin cancer, notorious for its 
resistance to chemotherapy and highly metastatic nature in the clinic. Over 50% 
of melanoma patients harboring BRAFv600E-activating mutations benefit from 
targeted therapies against BRAF (Chapman et al., 2011; Curtin et al., 2005; 
Davies et al., 2002). However, most patients who initially respond to BRAF 
inhibitors acquire drug resistance and relapse (Flaherty, 2011). Understanding 
the mechanisms by which tumors acquire resistance may lead to development of 
treatment strategies with enhanced clinical efficacy. Activation of AXL in breast 
and lung cancer cell lines can promote resistance to targeted therapies and 
provides new mechanisms of resistance to explore for melanoma patients (Liu et 
al., 2009; Zhang et al., 2012). Interestingly, upregulation of AXL occurs during 
acquired resistance to the PLX4720 BRAF inhibitor and expression of AXL has 
been observed in 30% of BRAF-mutant melanomas (Johannessen et al., 2010; 
Sensi et al., 2011; Villanueva et al., 2010). These observations suggest that 
combined targeting of both BRAF and AXL may prevent BRAF resistance in 
patients, or at least prolong the effects of current BRAF inhibitors. Indeed, 
treatment of human melanoma cells with AXL inhibitors in vitro decreased 
proliferation, migration, and invasion, supporting the notion that targeting AXL in 
combination with other proteins may have significant impact on patients with 
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metastatic melanoma (Sensi et al., 2011; Tworkoski et al., 2011). Additionally, 
expression of AXL is significantly more frequent in NRAS-mutated melanomas 
and suggests that AXL inhibitors may also selectively kill this subtype of 
melanoma. Our study provides additional support for the combinatorial use of 
AXL and BRAF inhibitors to treat melanoma patients and warrants further 
investigation to assess whether AXL underlies resistance to BRAF inhibitors.  
Future studies using our preclinical model of AXL and BRAF-driven melanoma 
will help distinguish the role of AXL in regulating resistance to mutant BRAF 
inhibitors.  
 The presence of cancer stem cells limits the response to anti-cancer 
treatments such as BRAF inhibitors. Recent studies have highlighted a link 
between EMT and the formation of cancer stem cells (Mani et al., 2008). In 
cancer cells, induction of EMT can generate cancer stem cells capable of self-
renewal, tumor initiation and acquired resistance to therapies. AXL exemplifies 
one signaling pathway that can be exploited in cancer cells known to induce 
EMT, regulate self renewal, and promote chemoresistance of cancer stem cells 
in vitro (Asiedu et al., 2014; Byers et al., 2013; Gjerdrum et al., 2010; Wilson et 
al., 2014). In human melanoma, expression of AXL is correlated with poorly 
differentiated tumors that have increased metastatic potential and resistance to 
treatment (Hoek et al., 2006). In our studies, overexpression of AXL accelerates 
melanoma onset more effectively than inducers of EMT such as snai1b (Caramel 
et al., 2013). However, tumors arising from malignantly transformed AXL-
expressing cells negatively correlated with an EMT gene signature. Results from 
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our RNA-Seq data suggest that the high degree of cellular plasticity and invasion 
acquired in AXL-overexpressing cancer cells is not mediated through EMT 
programs as previously suggested and indicates the physiological function of 
AXL may work though an alternative method. Interestingly the gene-set-
enrichment analysis of our RNA-Seq data identified a significant enrichment for 
factors involved in the blood coagulation system. Very little is known about the 
role of coagulation in cancer progression but studies suggest it can promote 
tumor cell spreading (Im et al., 2004) and anticoagulants can suppress cancer 
metastasis in experimental models and cancer patients (Gil-Bernabe et al., 
2013). Further studies are necessary to validate whether AXL is inducing 
coagulation to promote invasion in our zebrafish melanoma model. Nevertheless, 
these results indicate AXL may be part of a more effective therapy to target 
invasive and resistant cancer cells.  
 
Methods 
Generation of zebrafish melanoma models 
MiniCoopR plasmids was obtained from (Ceol et al., 2011) and individual 
clones were created by MultiSite Gateway recombination (Invitrogen) using full-
length open reading frames. Twenty-five pictograms of each miniCoopR clone 
and 25 pg mRNA encoding theTol2 transposase were microinjected into one-cell 
zebrafish embryos. Embryos were generated from an incross of 
Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- and p53-/-;mitfa-/- zebrafish. Injected animals 
with rescued melanocytes were grown up to adulthood and screened weekly for 
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the presence of nevi or visible tumors staring at 6 weeks of age. 
 
Measuring zebrafish tumor growth 
Tumor volume was determined in vivo with caliper. Five fish for each 
tumor type were monitored weekly to asses tumor growth. Tumors were 
measured as soon as the tumor became visible. A caliper was used to measure 
the length and width of the tumor and volume was calculated using a modified 
ellipsoid formula ½(Length x width2).  
 
Histological analysis of zebrafish tumors to analyze invasion 
Zebrafish with tumors were fixed overnight in 4% PFA and embedded and 
sectioned in paraffin. Sections were stained with hematoxylin and eosin.  
 
RNA sequencing of zebrafish tumors  
Total RNA was harvested from three miniCoopR-AXL-GFP melanomas 
and three miniCoopR-MITF-GFP melanomas using Qiagen RNeasy kit (Cat # 
74104). Quality of RNA was assessed using Bioanalyzer RNA 6000 Nano Chip 
and RNA-Seq libraries prepared using illumina TruSeq Stranded Total RNA 
Sample Prep Kit with Ribo-Zero (Cat # RS-122-2401). Sequencing was 
performed on Illumina HiSeq 2000 using 50 cycle single-read sequencing v3 kit 
(Cat # FC-401-3002). Illumina Fatq files were aligned using Novoalign to the 
zebrafish Zv9 genome. All high-throughput sequencing data sets will be 
submitted to Gene Expression Omnibus (GEO). 
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Figure 3.1.  AXL cooperates with BRAF to accelerate melanoma onset. (A) 
Transgenic zebrafish melanoma model overexpressing fluorescently tagged AXL 
generated by injecting Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/-  transgenic zebrafish 
embryos at 1 cell stage with the AXL-GFP miniCoopR plasmid. Injection of 
embryos results in overexpression of fluorescently tagged AXL in rescued 
melanocytes and can be visualized in the bottom image of a developing 
melanoma. MiniCoopR vector image modified from (Ceol et al., 2011). (B) 
Melanoma-free survival curves for Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- or p53-/-
;mitfa-/- injected with indicated miniCoopR plasmids (total number of fish for each 
survival curve analysis was generated from 2 independent experiments except 
Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- injected with AXL-polyA miniCoopR and 







































MITF-GFP miniCoopR Tg(mitfa:BRAF(v600E)); P53-/-; mitfa-/- (n=121)
AXL-GFP miniCoopR Tg(mitfa:BRAF(V600E)); P53-/-; mitfa-/- (n=106)
SETDB1 miniCoopR Tg(mitfa:BRAF(v600E)); P53-/-; mitfa-/-  (n=59)
AXL-POLYA miniCoopR Tg(mitfa:BRAF(V600E)); P53-/-; mitfa-/- (n=37) 
AXL-GFP miniCoopR P53-/-; mitfa-/- (n=45)
SNAIL1B-GFP miniCoopR Tg(mitfa:BRAF(V600E)); P53-/-;mitfa-/- (n=107)
Tg(mitfa:BRAF(V600E));
p53-/-;mitfa-/-
P value < .0001





Figure 3.2.  AXL cooperates with BRAF to transform primary melanocytes and 
promote tumor formation. (A) Nevi-free survival curves showing 
Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- injected with AXL-GFP, AXL-polyA, or 
MITF-GFP miniCoopR plasmid indicates overexpression of AXL in primary 
melanocytes accelerates nevi formation. (B) Nevi expressing fluorescently 
tagged AXL monitored every 2 weeks confirms GFP-expressing tumor mass 






























































AXL-GFP miniCoopR Tg(mitfa:BRAF(V600E)); P53-/-; mitfa-/-   n=58
AXL-POLYA miniCoopR Tg(mitfa:BRAF(V600E)); P53-/-; mitfa-/-    n=46
MITF-GFP miniCoopR Tg(mitfa:BRAF(v600E)); P53-/-; mitfa-/-    n=74
P value < .0001

















Figure 3.3.  AXL accelerates melanoma growth and enhances invasion in vivo. 
(A) Tumor volume area in AXL overexpressing melanomas compared to GFP 
control melanomas. (B) Sections of zebrafish melanomas at different time points 
of tumor progression stained with hematoxylin and eosin. At a later stage of 
tumor progression, 5 mm3, control melanomas grow outwards on the skin and do 
not break through and invade the basement membrane. AXL overexpressing 
melanomas start to invade through the basement membrane (arrows) at an early 
stage 1 mm3 and by 3 mm3 they have completely invaded through the skin into 
the underlying muscle.  
 




   











   
   
   











   
   
   

























Figure 3.4.  GSEA in AXL overexpressing tumors reveals negative correlation 
with EMT pathway. (A) Gene-set-enrichment analysis (GSEA) plots of gene 
expression signatures of Hallmark_Epithelial_mesenchymal_Transition. The 
barcode plot indicates the position of the genes in each gene set; red and blue 
colors represent positive and negative correlation with AXL expression. FDR, 






























Figure 3.5.  Experimental design to test the requirement of AXL in promoting 
melanoma onset, growth, and invasion. (A) Generation of zebrafish melanoma 
model lacking AXL expression will be generated by crossing p53-/-;mitfa-/-;axl-/- 
into the Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- genetic background. Embryos will 
be injected with control MITF-RFP miniCoopR plasmid and tumor onset, growth, 
and invasion will be compared to Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- injected 
with the same control MITF-RFP miniCoopR plasmid. (B) To test whether AXL is 
necessary in the tumor microenvironment to promote melanoma invasion the 
AXL-GFP miniCoopR plasmid will be injected into the 
Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/-;axl-/- genetic background and tumor onset, 
growth and invasion will be compared to Tg(mitfa:BRAF(V600E));p53-/-;mitfa-/- 
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Zebrafish as a model system for preclinical drug screening 
In this body of work we apply the zebrafish model system to identify novel 
signaling pathways regulating EMT and cancer cell invasion in vivo. We took 
advantage of the genetic and transparent attributes of the zebrafish and 
generated a novel in vivo EMT reporter called Tg(snai1b:GFP), which allows 
direct visualization of EMT in an intact animal. This transgenic line fluorescently 
labels snai1b-expressing cells undergoing EMT during development, including 
dorsal neural tube progenitors undergoing EMT to form Neural Crest (NC). The 
Tg(snai1b:GFP) was used to rapidly screen small molecules and identify novel in 
vivo inhibitors of EMT. We identified a multi-kinase inhibitor TP-0903, which 
potently blocks EMT by increasing RA biosynthesis. We provide the first study to 
implicate RA as an antagonist of EMT and establish a complementary in vivo 
approach to identify effective EMT inhibitors for clinical application.   
Through our chemical genetic screening approach to identify inhibitors of 
EMT, we gained insight into signaling pathways that contribute to invasion 
mechanisms and can be rationally targeted as a therapeutic strategy. Our 
findings of multi-kinase inhibitor TP-0903 presented AXL as a therapeutic target 
and a candidate for promoting cancer cell invasion in vivo. TP-0903 was 
rationally designed to target AXL RTK and this strongly suggests AXL is a 
candidate in promoting EMT and invasion of NC cells and NC derived cancers 
like melanoma. We tested the ability of AXL to accelerate cancer progression in 
vivo by generating a zebrafish melanoma model overexpressing AXL.  We found 
AXL cooperates with BRAF to accelerate melanocyte transformation, tumor 
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onset, growth, and invasion in vivo. These studies provide the first evidence that 
AXL can cooperate with BRAF to promote melanoma in vivo and support the 
development of AXL inhibitors for the treatment of melanoma. Additionally the 
establishment of an in vivo model of AXL dependent invasion will help elucidate 
the AXL dependent mechanisms driving EMT, invasion, and resistance to 
therapies.   
 Together these studies demonstrate the strength of using zebrafish for 
preclinical drug screening and highlight zebrafish as a key model system to help 
identify functional regulator of cancer progression in vivo.   
 
Developing AXL inhibitors for cancer therapy 
Here we provide clear evidence supporting the clinical development of 
AXL kinase inhibitors as an antimetastatic agent. Currently there are several 
small molecule inhibitors being developed to target AXL, including TP-0903 that 
is in preclinical development by Tolero Pharmaceuticals (Tolero 
Pharmaceuticals, 2015). TP-0903 is a multitargeted kinase inhibitor with high 
potency against AXL (IC50 = 27 nmol/L) and significant efficacy against multiple 
types of cancers in vitro including leukemia, pancreatic, and lung cancer (Mollard 
et al., 2011; Sinha et al., 2015). Other multi-kinase inhibitors being actively 
developed with inhibitory activity against AXL include MP470 (Amuvatinib), which 
has been shown to synergize with docetaxel and is cytotoxic to gastrointestinal 
tumors and breast cancer (Mahadevan et al., 2007). Currently compound R428 
(BGB324) is one of the most potent and highly selective AXL inhibitors published 
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and entered phase 1 clinical trial in 2013 (Sheridan, 2013). In preclinical studies 
R428 reduced invasion of cancer cells in vitro and suppressed metastasis in 
mouse models of metastatic breast cancer (Holland et al., 2010). Additionally, 
SGI-7079 is another highly specific AXL inhibitor that is currently in phase 2 
clinical trials for demonstrating that it can decrease malignant properties in 
inflammatory breast cancer and can overcome resistance to EGFR inhibitors in 
NSCLC in preclinical studies (Byers et al., 2013; Wang et al., 2013). So far 
inhibition of AXL signaling as a cancer treatment strategy has shown great 
promise and multiple drug companies are pursuing the clinical development of 
other AXL inhibitors (Wu et al., 2014). Future studies will benefit from the 
zebrafish model of AXL dependent melanoma invasion developed in our studies 
to evaluate and identify effective AXL inhibitors in vivo.  
Monoclonal antibodies are also being generated as a novel strategy to 
inhibit AXL signaling. Antibodies have been developed against the extracellular 
domain of AXL and the AXL ligand Gas6 (Angelillo-Scherrer et al., 2005; Ye et 
al., 2010). Anti-AXL monoclonal antibody YW327.6S2 has shown highly specific 
activity against AXL and can attenuate tumor growth and reduce metastasis in a 
xenograft model of breast cancer (Ye et al., 2010). The Anti-Gas6 antibody has 
not been investigated for the treatment of cancer but it has proven to be useful in 
neutralizing Gas6 activity and reducing signaling of all AXL family members 
(Angelillo-Scherrer et al., 2005). Moving forward with the use of AXL-targeted 
therapies in human cancers, the development of appropriate biomarkers will be 
crucial to identify a population of patients who will respond and benefit from 
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treatment with AXL inhibitors. Currently no genetic mutations have been 
associated with the oncogenic properties of AXL and using IHC to detect AXL 
overexpression seems to be the method of choice. An appealing biomarker for 
clinical studies currently being considered is the use of a radiolabelled anti-AXL 
antibody to image AXL expression in vivo (Nimmagadda et al., 2014). This 
approach is highly amenable to immuno-PET imaging which could be 
incorporated into clinical studies for AXL inhibitors. One potential biomarker that 
has not been explored is the quantification of soluble AXL in blood serum 
samples of cancer patients. Soluble AXL (sAXL) is derived from proteolytic 
cleavage of the extracellular portion of membrane-bound AXL or is a product of 
alternative splicing (Verma et al., 2011).  The biological significance of sAXL is 
unclear but may act to inhibit AXL signaling through binding and depleting its 
ligand GAS6 or, alternatively, act to concentrate GAS6 locally to activate AXL.  
Our collaborator Dr. David Bearrs and his group showed a significant increase in 
sAXL in advanced stages of pancreatic cancer patients compared to controls, 
with high/intermediate levels corresponding to poor outcomes (personal 
communication). We hypothesize that intermediate/high levels of sAXL and/or 
GAS6 will indicate metastasis in cancer patients and represent a novel biomarker 
for informing cancer treatments. Future studies are required to determine if sAXL 
is an appropriate biomarker to identify patients with advanced metastatic disease 
that will successfully respond to treatment with AXL inhibitors.  
One outstanding question in the development of AXL inhibitors for clinical 
use is how does AXL inhibition impact cancer immunity? AXL and the rest of the 
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TAM family members are expressed by dendritic cells, macrophages, and 
immature natural killer cells of the immune system (Lemke and Rothlin, 2008). All 
TAM receptors function in the clearance of apoptotic cells and TAM knock out 
mice develop a plethora of autoimmune disorders. This is in part due to the 
normal function of AXL in suppressing inflammatory cytokine production in innate 
immune cells (Sharif et al., 2006). Loss of AXL in an inflammation-associated 
colorectal cancer model augments production of inflammatory cytokines that 
enables a tumor-promoting environment and increased tumor formation (Bosurgi 
et al., 2013). These observations raise the possibility of potential adverse effects 
of AXL inhibitors in the treatment of cancer. However, other studies provide 
evidence that inhibition of AXL signaling can enhance in vivo activity of natural 
killer cells against cancer cells and restrain cytokine production in tumor 
associated macrophages to suppress tumor growth (Paolino et al., 2014; Ye et 
al., 2010). These studies indicate AXL inhibitors can modulate immune cell 
function to promote antitumor immunity and underscore the importance of 
understanding the tissue and cell type specific functions of AXL in the tumor 
microenvironment to develop effective therapeutics.  
 
The role of retinoids in cancer therapy 
All-trans-retinoic acid (ATRA), an active metabolite of vitamin A, is an 
attractive anticancer therapy for the treatment of a variety of cancers because of 
its low toxicity and specific effects on inhibiting cell proliferation, inducing 
differentiation, and apoptosis (Connolly et al., 2013). Retinoid therapies are being 
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incorporated into the clinic as differentiation agents to target dormant cancer 
stem cells (Nasr et al., 2008; Reynolds, 2000). Our findings provide an 
alternative viewpoint on retinoid therapy and indicate the positive effects of 
retinoids may also be due to its role in blocking EMT. Currently ATRA derivative 
13-cis-retinoic acid (13-cis-RA) is successfully used in the treatment of children 
with high-risk neuroblastoma to reduce the risk of recurrence after chemotherapy 
and stem cell transplantation and increase long-term survival (Matthay et al., 
2009). However, ATRA is only routinely and effectively used for the treatment of 
cutaneous T cell lymphoma (Duvic et al., 2001) and acute promyelocytic 
leukemia (APL) (Bushue and Wan, 2010; Tallman et al., 1997). Given our 
findings that implicate RA in the elimination of disseminated cancer cells through 
the inhibition of EMT, why are retinoids not being used to treat a wider range of 
cancers? The antitumor activity of ATRA has been studied in several animal 
model systems and clinical trials but limited chemopreventative and therapeutic 
success has been observed in solid tumors (Connolly et al., 2013; Schenk et al., 
2014). This may be partly due to the frequent epigenetic silencing of retinoic acid 
receptor β (RARβ) in tumors (Glasow et al., 2008; Lotan et al., 1995; Mehrotra et 
al., 2004; Sirchia et al., 2000), which may render treatment with ATRA 
ineffective. Re-expression of RARβ has been seen after treatment with 
epigenetic inhibitors (Schenk et al., 2012; Sirchia et al., 2002). Several studies 
have indicated that the combination of ATRA and epigenetic inhibitors may be an 
effective strategy to restore the therapeutic effects of ATRA in RARβ silent 
cancer cells (Pili et al., 2012; Qian et al., 2005; Raffoux et al., 2010; Sirchia et al., 
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2002). These studies suggest the optimized use of retinoids to treat solid tumors 
may be dependent on evaluation of RARβ expression in solid tumors and 
combination treatment with epigenetic inhibitors. Future studies are required to 
evaluate the effectiveness of RA to both eliminate disseminated cancer cells 
through the inhibition of EMT and promote differentiation of cancer stem cells in 
cancer patients with solid tumors. 
Overall, our approach to develop an in vivo EMT reporter to identify 
effective inhibitors of EMT has revealed novel signaling pathways regulating EMT 
during development and yielded a potent small molecule inhibitor of EMT. 
Additionally our screen provided rational therapeutic targets for melanoma 
treatment and a new viewpoint on retinoid therapy that that will help inform 
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